Exhibit 10.325  CONFIDENTIAL
  
  REDACTED VERSION  [***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE COMMISSION. 
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED
PORTIONS.  AGREEMENT  THIS AGREEMENT is made
effective as of the 1st day of July, 2003 (the Effective Date), between The
American National Red Cross, a not-for-profit corporation chartered by an act
of Congress, 36 U.S.C. § 30010 et  seq., having a principal
place of business at 2025 E Street, NW, Washington, DC 20006-5009 (ARCHQ),
and Chiron Corporation, a Delaware corporation (Chiron) having its offices
at 4560 Horton Street, Emeryville, California 94608-2916 (the Agreement).  Background  WHEREAS, ARCHQ, operating through its
Biomedical Services division (ARC) provides, inter alia, blood services,
including the collection of blood from donors, and the screening, packaging and
distribution of blood, blood components and derivatives to those in need of
such services;  WHEREAS, ARC currently screens for itself
and for other blood banks in the United States, human blood samples for viruses
such as Human Immunodeficiency Virus type-1 (HIV-1) and Hepatitis C Virus
(HCV)
by performing screening, including without limitation amplified nucleic acid
screening, in five (5) of its national testing laboratories located in San
Diego, Detroit, St. Louis, Charlotte and Philadelphia and as further identified
on Schedule 1.26 (each, an NTL, and collectively, the NTLs);  WHEREAS, Chiron and ARCHQ are parties to
that certain Sale and Servicing Agreement effective as of August 1, 2002
(the 2002
Agreement), pursuant to which Chiron sells to ARC, and ARC
purchases from Chiron, certain assays and blood screening instruments to
conduct nucleic acid amplification screening to detect the presence of certain
viruses in blood, including HIV-1 and HCV;  WHEREAS, Chiron, together with its
collaboration partner, Gen-Probe Incorporated (Gen-Probe), is developing an
assay which can be used to conduct amplified nucleic acid tests to detect the
West Nile Virus in pooled and single donor blood samples (the WNV Assay);  WHEREAS, substantial further development
and testing of the WNV Assay is necessary before Chiron and Gen-Probe may seek
to obtain FDA approval for the commercial distribution and use of such WNV
Assay;  WHEREAS, the costs and efforts required for
such further development and testing far exceed those that Chiron and Gen-Probe
will undertake without assistance and collaboration from other entities, and
the absence or delay of such assistance and collaboration of those entities
would significantly delay the further development and testing, and, thus, the
commercial availability of the WNV Assay in the Territory;  1 
   WHEREAS, the rapid development and
availability of the WNV Assay for the testing of blood donations is of critical
importance to ARCs mission and obligation to ensure the safety of the blood
products it manufactures, and to the protection of the public health;  WHEREAS, ARC desires to collaborate with
and support Chiron and Gen-Probe in the further development and testing of the
WNV Assay necessary for obtaining FDA approval or licensing for commercial
distribution of the WNV Assay, subject to the terms and conditions stated
below:  NOW, THEREFORE, in consideration of the
foregoing premises and of the mutual covenants of the Parties hereinafter
contained, the Parties hereto hereby agree as follows:  ARTICLE 1 - DEFINITIONS  Capitalized terms used
and not otherwise defined in this Agreement shall have the following meanings:  1.12002
Agreement shall mean that certain Sale and Servicing Agreement
effective as of August 1, 2002, between ARCHQ and Chiron pursuant to which
Chiron sells to ARC, and ARC purchases from Chiron, certain assays and blood
screening instruments to conduct nucleic acid amplification screening to detect
the presence of certain viruses in blood, including HIV-1 and HCV.  1.2Affiliate
shall mean, with respect to any specified Person, any other Person which
directly or indirectly controls, is controlled by, or is under common control
with, the specified Person.  For
purposes of this definition, the term control shall mean (i) ownership
interests representing more than fifty percent (50.0%) of the equity or more
than fifty percent (50.0 %) of the ordinary voting power or more than fifty
percent (50.0%) of the general partnership interests are, at the time such
determination is being made, held, directly or indirectly, by such Person, or
(ii) whether used as a noun or verb, refers to the possession, direct or
indirect, of the power to direct, or cause the direction of, the management or
policies of any Person, whether through the ownership of voting securities, by
contract or otherwise.  1.3Agreement
shall have the meaning set forth in the introductory paragraph of this
agreement.  1.4Amended
Order Request shall have the meaning set forth in
Section 2.5(b).  1.5ARC Fiscal
Year shall mean each July 1 to June 30.  2 
   1.6ARC
Indemnitees shall have the meaning set forth in Section 7.5.  1.7Blood
Screening Field shall mean the nucleic acid probe-based screening
of (i) human blood, recovered and voluntary source plasma, platelets or other
blood products intended for transfusion or other administration to humans,
including autologous donors and (ii) recovered and voluntary source plasma for
further manufacture, but specifically excluding paid source plasma intended for
further manufacture.  1.8Blood
Screening Systems shall mean the instrument(s) and the related
software for DNA/RNA amplified assay processing purchased by ARC from Chiron
under the 2002 Agreement, including the Software acquired by ARC under this
Agreement.  1.9Chiron
Indemnitees shall have the meaning set forth in Section 7.6.  1.10Confidential
Information means any and all technical, business and other
information and materials disclosed by or on behalf of one Party to the other
Party pursuant to this Agreement or during discussions leading to the execution
of this Agreement, except to the extent that the receiving Party can provide
evidence that such information:  (a)is
known to the receiving Party prior to its disclosure by the disclosing Party; or  (b)is
obtained by the receiving Party from a source other than the disclosing Party
which source (i) did not require the receiving Party to hold such information
in confidence; or (ii) did not limit or restrict the receiving Partys use
thereof, or  (c)has
become public knowledge otherwise than through the fault of the receiving
Party; or  (d)has
been developed by the receiving Party independently of the information received
from the disclosing Party as shown by the receiving Partys written records; or  (e)is
required to be disclosed by the receiving Party by law or for the purpose of
complying with governmental regulations and/or the obligations of the receiving
Party to a licensing or regulatory authority in connection with this Agreement,
provided the receiving Party provides the disclosing Party with prompt notice
of such disclosure so that the disclosing Party has the opportunity to seek a
protective order or other appropriate remedy.  3 
   1.11Damagesmeans
any liability for bodily injury, death or property damage (whether arising out
of fault, strict liability or otherwise) in the form of an obligation, loss,
fine, judgment for damages, arbitration award, settlement amount, penalty or
claim, and all reasonable costs and expenses related thereto (including
reasonable costs of investigation, fees and expenses payable to outside
counsel, independent accountants and similar professional advisors or
consultants, but not including any corporate allocation for use, of similar
in-house services or facilities).  1.12Data
shall have the meaning set forth in Section 6.7.  1.13Documentation
shall mean text material, including the Package Insert and Software manuals,
that describes the design, functions, operation, or use of the WNV Assays and
related Software, that is delivered by Chiron to ARC.  Documentation for the Software shall be the same that is provided
to licensees of such Software generally.  1.14Effective
Datemeans the date set forth in the introductory paragraph on the
first page of this Agreement.  1.15Enhancement
means an alteration or addition to a Product [***], for which a separate
fee will be imposed.  1.16FDA
shall mean the United States Food and Drug Administration, or any successor
entity thereto.  1.17Force
Majeure Event shall have the meaning set forth in Section 9.1.  1.18Gen-Probe
shall mean Gen-Probe Incorporated, a Delaware corporation.  1.19HCV
means the Hepatitis C virus.  1.20HIV-1
means Human Immunodeficiency virus type 1.  1.21Indemnifying
Party shall have the meaning set forth in Section 7.8.  1.22Indemnitee
shall have the meaning set forth in Section 7.8.  1.23IP Claim
shall have the meaning set forth in Section 7.7(a).  1.24IQA
Procedures shall have the meaning set forth in Section 2.6.  1.25Modified
Order shall have the meaning set forth in Section 2.5(c).  1.26Multi-Flavivirus
Assay means a nucleic acid probe assay that is capable of detecting
the presence of more than one member of the  4 
   Japanese encephalitis
virus complex (which includes St. Louis Encephalitis, Kunjin, Japanese
encephalitis, Murray Valley encephalitis viruses, among others) and/or the
Dengue virus, for use in the Blood Screening Field, and which assay shall have [***].  1.27Normal
Support Hours shall have the meaning set forth in Schedule 4.0,
paragraph 2.4.  1.28NTLsmeans
ARCs national testing laboratories identified on Schedule 1.26.  1.29Outbreak
Testing means screening of samples from up to [***] individual blood
donations in each of the first and second twelve Testing Months during the Term
using a WNV Assay in Single Unit Testing format, where such Single Unit Testing
is determined by ARC to be necessary for any reason, e.g., regional outbreaks of
the West Nile Virus.  1.30Package
Insertshall mean the draft package insert to be submitted to the
FDA for approval for the applicable WNV Assay and attached to Schedule 2.0,
as the same may be amended from time to time.  1.31Panel
shall have the meaning set forth in Section 12.4.  1.32Party or
Parties means Chiron, ARC or Chiron and ARC, respectively.  1.33Person
shall mean an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, pool,
syndicate, sole proprietorship, unincorporated organization, governmental
authority or any other form of entity not specifically listed herein.  1.34Pooled
Testingmeans the conduct of screening of pools of samples from
blood donations, including allogenic and autologous donors, generally
consisting of:  (a)[***]
and  (b)[***]  1.35Products
shall mean WNV Assay and related Software.  1.36Reagent
Utilization Factor means, with respect to a specified time period,
the [***].  5 
   1.37Regulations
shall mean all applicable and then current laws, requirements, regulations,
standards, Package Insert, and directives,promulgated by the FDA or any other state
or federal authorities.  1.38Reportable
Result means a result obtained through the use of a WNV Assay and
Blood Screening System from which it is determined to release for use or hold
and not use (a) a blood donation intended for transfusion or for further
processing for other administration to humans or (b) a product derived from
such donation.  1.39Requirement
shall have the meaning set forth in Schedule 4.0, paragraph 3.3.  1.40Rush Order
shall have the meaning set forth in Section 2.5(d).  1.41Services
shall have the meaning set forth in Article 4.  1.42Single Unit
Testingmeans screening of blood donations consisting of (i)
screening a sample from each individual blood donation using a WNV Assay,
including allogenic and autologous donors, (ii) screening of individual samples
relating to tissue and/or organ donation and (iii) follow up repeat testing of
positive results.  1.43Softwaremeans
the following software programs, including any subsequent Upgrades released
during the Term of this Agreement that ARC elects to acquire pursuant to this
Agreement, but specifically excluding NAT Tracker:  Procleix® WNV Assay
Software, Version 2.0.1.0  1.44Specificationsshall mean with respect to each Product, the specifications, tests,
procedures, process description, storage and handling requirements and other
information relating to such Product and packing thereof prepared by Chiron,
its Affiliates, Gen-Probe or other Third Party manufacturers provided to ARC by
Chiron under separate cover, including without limitation such information
contained within the Documentation, which may be amended from time to time by
Chiron after as much advance written notice to ARC of such amendment as is
reasonably practicable is given; provided, however that the foregoing
information shall be consistent with the IND and/or other information required
by the Regulations of each of Chiron and Gen-Probe, or any of their respective
Affiliates, in connection with their performance under this Agreement.  1.45Standing
Order shall have the meaning set forth in Section 2.5(b).  6 
   1.46Technologists
means the employees of ARC trained at a facility of ARC by either a Trainer or
Chiron technical representative.  1.47Term
shall have the meaning set forth in Section 8.1.  1.48Territory
means the United States of America, including Puerto Rico, Guam and all other
protectorates of the United States.  1.49Testing
Monthmeans a calendar month during which ARC makes use of the
Products to generate Reportable Results for [***] of the blood donations
screened by ARC during such month for HCV and HIV-1 under the 2002 Agreement.  1.50Third
Party shall mean any Person other than ARC, and Chiron.  1.51Trainer
shall mean an employee of ARC trained by Chiron to perform troubleshooting,
training of Technologists and such other services to ARC as set forth in the
Train the Trainer program referenced in paragraph 2.2 of Schedule 4.0.  1.52Upgrades
means (i) changes to a Product that are made available to correct design
faults, discrepancies or defects (so called bugs), (ii) alterations to a
Product [***],
for which a separate charge will not be imposed and (iii) changes to a Product
that are mandated by the FDA.  1.53West Nile
Virus means a mosquito-borne flavivirus, classified as a member of
the Japanese encephalitis virus complex. 
The virus primarily infects birds, but has been found in several other
animal species, including horses, dogs, alligators and humans.  Humans are a dead-end host for the virus,
hence the majority of infected humans (~80 %) are asymptomatic.  Another ~20% of infected individuals develop
a mild fibrile disease, sometimes accompanied by rash.  A final ~1% of all humans infections result
in severe and fatal encephalitis.  The
virus has been shown to be transmissible by blood transfusion or by transplant
with infected organs.  1.54WNV Assays
shall mean the nucleic acid probe assays under development by Chiron and Gen-Probe
that are provided by Chiron under this Agreement, which shall be used by ARC in
the Territory to screen for the West Nile Virus in the Blood Screening Field
pursuant to this Agreement, and which assays shall have [***], as defined in the
Specimen Collection, Storage and Handling section of the Package Insert.  7 
   ARTICLE 2 - PROVISION OF WNV ASSAYS  2.1Supply,
Handling and Storage Obligation. 
During the Term of this Agreement Chiron agrees to supply to ARC the WNV
Assays specified on Schedule 2.0 to permit each NTL to conduct
screening of blood donations in the Territory. 
ARC agrees to store and handle all WNV Assays in accordance with the
applicable Package Insert and other Specifications.  Any WNV Assays lost or damaged due to failure to comply with the
applicable Package Insert and such Specifications will be replaced at ARCs
expense.  2.2Purchase
Obligation.  During the Term of this
Agreement, ARC agrees to acquire from Chiron ARCs requirements of WNV Assays
in the Territory.  However, nothing in
this Agreement will restrict the right of ARC to evaluate new technologies and
products commercially available from Third Parties or to perform, in its
discretion, any confirmatory and supplementary nucleic acid screening with
Third Party products.  2.3Packing
and Delivery of WNV Assays.  Chiron
shall ensure that all WNV Assays will be suitably packed and transported to
ensure safe transport to ARC in accordance with applicable Specifications and
delivered to ARCs designated NTL, and each delivery will be accompanied by a
packing slip indicating the quantity delivered, the Product lot number(s) and
the expiration date(s).  WNV Assays will
be delivered during normal business hours and accompanied by storage
instructions and arrive at the temperatures specified in the applicable
Specifications or Package Insert.  The
WNV Assays will be delivered in kit form, with appropriate distribution between
screening tests, discriminatory tests and related calibrators.  2.4Shipping.  Except as set forth in this
Section 2.4, all shipping, handling and risk of loss charges for the
Products will be borne entirely by Chiron on shipments to the NTLs pursuant to
a Standing Order or a back order and will be shipped, fully insured, to the
designated NTL.  All shipping, handling
and risk of loss charges for shipping requests other than to an NTL as
requested by ARC, and all incremental shipping, handling and risk of loss
charges for Modified Orders or Rush Orders, will be borne by ARC.  2.5Forecasts
and Orders.  (a)ARC
will provide Chiron with a written twelve month forecast by NTL of its
requirements of WNV Assays (each a Product Requirements Forecast) for each
ARC Fiscal Year during the Term of this Agreement on or prior to the
May 1st immediately prior to the commencement of such ARC Fiscal
Year.  Such Product Requirements
Forecasts shall include the requested delivery dates for WNV Assays for each
NTL.  ARC may modify its Product
Requirements Forecasts for any ARC Fiscal Year upon thirty (30) days advance
written notice, provided that if ARC elects to suspend  8 
   use of WNV Assays for any
period of greater than thirty (30) days, ARC shall provide not less than ninety
(90) days notice.  (b)Each
month within the then current Product Requirements Forecast shall constitute a
standing order (Standing Order) and may be amended either on a temporary
(i.e., with respect to one or two (2) months) basis by ARC (an Amended
Order Request).  ARC will
provide Chiron as much advance written notice as reasonably practicable if ARC
desires to amend its Standing Order with an Amended Order Request.  (c)If
the variance between any Amended Order Request exceeds [***] of that originally projected
in the Standing Order for the same month(s) in the Product Requirements
Forecast (measured on a number of WNV Assays requested), Chiron will notify ARC
within five (5) business days after receipt of the amendment as to whether it
accepts such Amended Order Request and the delivery date(s) referenced
therein.  If Chiron doesnt respond to
an Amendment Order Request within the five (5) day period, acceptance of the
Amended Order Request shall be presumed by the Parties.  If an Amended Order Request is accepted
unmodified, Chiron agrees to deliver such amounts of WNV Assays on the delivery
date(s) stated therein.  If an Amended
Order Request is not accepted, the Parties will use all commercially reasonable
efforts to agree on modifications to the Amended Order Request (a Modified
Order), subject to Gen-Probes ability to accommodate Chirons
requests for changes in forecasted amounts. 
Chirons failure, if any, to deliver any volume of WNV Assays in excess
of the Standing Order amount would not constitute a breach by Chiron under this
Agreement, provided that Chiron uses commercially reasonable efforts to deliver
such increased volume in accordance with an accepted Amended Order Request or
Modified Order and notifies ARC in writing as promptly as practicable of the
extent Chiron expects to deliver such increased volume.  (d)Shipments
of WNV Assays based on Standing Orders shall be made by Chiron automatically to
each NTL every fourteen (14) or twenty-eight (28) days at the election of each
NTL.  Shipments of WNV Assays pursuant
to Standing Orders shall always take place within the first three (3) days of a
calendar week.  These shipment policies
may be altered by agreement between Chiron and any NTL.  From time to time, ARC may request that a
portion of a Standing Order for Products be shipped for the same day or next
day delivery (a Rush Order). Chiron shall use commercially reasonable efforts
to ship Rush Orders within twenty-four (24) hours after such request is made.  9 
   2.6IQA
Procedures.  As of the Effective
Date, Chiron and ARC have reviewed and agreed to adapt and adopt the existing
IQA Procedures approved pursuant to the 2002 Agreement for quality assurance
testing of WNV Assays received by ARC and/or any of its NTLs under this
Agreement (IQA Procedures). 
Chiron and ARC must agree to any modifications to such IQA Procedures.
The IQA Procedures include procedures for testing and notice to Chiron and for
implementing the return of WNV Assays for replacement.  Chiron agrees to replace, at its sole cost
and expense, WNV Assays which fail the IQA Procedures.  If testing by Chiron or its supplier
confirms the non-conformity of the WNV Assays, Chiron will bear the shipping
costs associated with replacement.  If
Chirons testing provides reasonably acceptable evidence that the WNV Assays do
conform to their Package Insert, the shipping costs incurred by Chiron will be
reimbursed by ARC.  The principal
inspection and testing and acceptance point by ARC for WNV Assays under this
Agreement will usually be the NTLs. 
However, the inspection, testing and acceptance activities may take
place at any point, including Chirons facility, with prior notice to Chiron.  2.7Technical
Support.  Chiron will provide ARC
with technical support to facilitate the operation by ARC of the WNV Assays on
the Blood Screening Systems in accordance with the terms set forth in Schedule 4.0.  2.8Nature
of Screening.  ARC acknowledges that
it has determined, in its sole discretion, to use the WNV Assays supplied by
Chiron to conduct Pooled Testing.  If
ARC desires to change from Pooled Testing to Single Unit Testing or to any
other pool size, ARC and Chiron shall enter into an amendment to this Agreement
reflecting any additional instrumentation or any other amendments that may be
applicable by reason of such change.  2.9Performance
Objectives.  (a)Chiron
hereby acknowledges that the accuracy and operational efficiency of blood
screening tests is of critical importance to ARC.  Accordingly, Chiron and ARC have agreed to establish the certain
performance objectives for the Products set forth on Schedule 2.9
hereto (the Performance Objectives). 
Chiron and ARC acknowledge the Performance Objectives set forth on Schedule 2.9
represent Chirons expectations regarding the Products based on results
obtained through the use of the Products during their development.  Accordingly, Chiron does not represent or
warrant that the Products will be capable of achieving the Performance
Objectives.  Notwithstanding the
foregoing, Chiron, together with ARC, will monitor the actual performance of
the Products on a quarterly basis throughout the Term beginning
September 1, 2003 as against the Performance Objectives set forth on Schedule 2.9
(each period, a Performance Measurement Period).  [***]  10 
   (b)If
the FDA requires any greater analytical sensitivity level than that set forth
in the Performance Objectives on Schedule 2.9, Gen-Probe and Chiron
shall take all reasonable steps to attain the required sensitivity.  If the only reasonable means by which to
attain the required sensitivity is reduced pool size, ARC and Chiron will
negotiate in good faith to achieve reasonable and equitable distribution of the
attendant incremental cost while striving to mitigate costs to either party.  ARTICLE 3 -BLOOD SCREENING
SYSTEMS; SOFTWARE  3.1Blood
Screening Systems.  (a)General.  The ARC shall use the WNV Assay only on the
Blood Screening Systems purchased and maintained pursuant to the 2002
Agreement.  Chiron bears no
responsibility with respect to any use of the WNV Assays on instrument systems
other than the Blood Screening Systems.  (b)Upgrades.  All Blood Screening Systems shall be revised
as needed to incorporate Upgrades necessary to perform the WNV Assay at no
additional cost to ARC.  Chiron shall
coordinate the installation of Upgrades with ARC to minimize the impact on
ARCs operations.  If requested by
Chiron, ARC shall return prior versions of Blood Screening Systems to Chiron
within a reasonable period of time following completion of the Upgrade
installation.  (c)Warranties.  Use by ARC of the WNV Assay on the Blood
Screening Systems in accordance with this Agreement shall not void the
warranties set forth in Section 3.1(e) of the 2002 Agreement.  3.2Software
and Documentation.  (a)Software.  Chiron agrees to provide to ARC, at no
additional charge, all Software and Documentation necessary to run the WNV
Assays on the Blood Screening Systems as contemplated by this Agreement;
provided, further that Chiron shall make available to ARC, at no additional
cost, all of the same to the extent that any Software has been provided by a
licensor other than Chiron.  (b)Title.Chiron, or the applicable licensor of
the Software to be provided hereunder, shall own and retain title to the
Software, including all intellectual property rights embodied therein.  Any copy which ARC makes of the Software, in
whole or in part, is and shall  11 
   remain the property of
Chiron or the applicable licensor. If ownership of the Software or any work
product does not result as provided in this Agreement or by operation of law,
then the Parties each assign and shall cause their respective employees,
agents, and contractors to assign, without further consideration, the ownership
thereof, including all associated intellectual property rights, as necessary to
give effect to the ownership terms specified in this Agreement.  Each Party agrees to perform, at the
reasonable request of the other Party, such further acts as may be necessary or
desirable to transfer ownership of, and to perfect and defend, the Software in
order to give effect to such ownership terms.  (c)Upgrades.  All Software shall be revised as needed to
incorporate Upgrades at no additional cost to ARC.  Chiron shall coordinate the installation of Upgrades with ARC to
minimize the impact on ARCs operations. 
If requested by Chiron, ARC shall return prior versions of Software to
Chiron within a reasonable period of time following completion of the Upgrade
installation.  (d)License.  Chiron hereby grants, and ARC hereby
accepts, subject to the terms and conditions of this Agreement, a nonexclusive,
nontransferable and nonassignable (except as permitted under this Agreement)
object code license (or sublicense, as applicable) to use the Software at the
NTLs solely for ARCs own use in connection with the operation of the WNV
Assays on the Blood Screening Systems during the Term of this Agreement, and to
copy the Software solely for the purposes expressly authorized under this
Section 3.2.  In addition, Chiron
hereby grants to ARC the right to use the Documentation in connection with its
use of the Software hereunder. 
Documentation may not be copied. 
Additional copies of the Documentation may be obtained from Chiron,
subject to payment of Chirons reasonable copying charges then in effect.  No right to use, copy, display, or print the
Software or Documentation, in whole or in part, is granted, except as expressly
provided in this Agreement.  (e)Confidentiality.  ARC acknowledges that the Software is the
proprietary intellectual property of Chiron or the applicable
manufacturer/licensor, and ARC shall take reasonable precautions to protect the
Software and to prevent the disclosure thereof to Third Parties.  (f)Restrictions
on Use.  The grant of rights stated
in this Section 3.2 is subject to the terms and conditions of this
Agreement as well as the following restrictions:  12 
   (i)Use
of the Software may be subsequently transferred to other NTLs, provided (A) the
total number of NTLs at which the Software is used does not exceed the number
of NTLs specified in this Agreement and (B) ARC provides Chiron with written
notice thirty (30) days before such transfer.  (ii)In
the event that disaster or other circumstances affecting ARC prevents ARC from
using the Software at the NTLs identified in this Agreement, the effected NTLs
shall have the right to use the Software at a disaster recovery facility
without prior notice to Chiron, but shall promptly notify Chiron as soon as
circumstances permit.  (iii)ARC
shall not use (or cause to be used) the Software for rental, in the operation
of a service bureau or for any similar purpose, nor shall ARC allow access to
the Software through terminals located outside ARCs business premises by
persons who are not ARCs employees or authorized agents, contractors or
representatives.  (iv)ARC
shall not distribute the Software, in whole or in any part, to any Third Party
or parties, nor permit its sublicensing, leasing, or other transfer, except as
permitted under Section 13.3 of this Agreement.  (v)ARC
shall not, either directly, or through a Third Party, reverse engineer,
disassemble or decompile the Software, or make any attempt in any fashion
except as specifically provided in this Agreement to obtain the source code to
any Software.  (vi)Any
use of the Software not in accordance with this Agreement, or any modification
or alteration of the Software not expressly authorized in writing by Chiron,
shall be deemed a breach of this Agreement.  (vii)Upon
expiration or termination of this Agreement, ARC shall (A) cease all use of the
Software and the Documentation; (B) return to Chiron the Software and the
Documentation and any copies thereof (unless required to retain such material
for regulatory purposes); and (C) erase from memory all copies of the Software
(unless required to retain such material for regulatory purposes).  ARC shall certify in writing to Chiron that
it has not retained the Software and Documentation or any copies thereof
(unless required to retain such material for regulatory purposes).  13 
   (g)Electronic
Records; Electronic Signatures. 
Chiron shall utilize commercially reasonable efforts to develop and
install Upgrades necessary to ensure the Software is capable of being utilized
in compliance with 21 CFR Part 11.  ARC
shall have the right to perform an audit of the Software to ensure such
compliance.  (h)Warranties;
Limitation of Liability.  (i)Performance.  Chiron warrants that the Software, under
normal use and service, will perform all of the material functions described in
the Documentation of such Software. 
Chiron warrants that the Documentation shall be free from material
defects in materials and workmanship. 
If any such defect or deviation appears during the applicable periods,
the Software or Documentation may be returned to Chiron for replacement by
Chiron without charge;  (ii)Anti-Virus.  Chiron warrants that to the best of its
knowledge after employing reasonable technical means to detect computer
viruses, the Software at the time of delivery will not contain any virus or
computer software code, routines or devices designed to disable, damage,
impair, or erase the Software or other software or data.  For failure to comply with this warranty,
Chiron shall, at Chirons expense, immediately replace all copies of the
affected Software in the possession of ARC; and  (iii)Chiron
warrants that as of the Effective Date of this Agreement it has full rights and
authority to license the Software to ARC, or the authority to do so without
infringing the rights of any Third Party. 
Chiron shall not incorporate any other software having any limitation on
its use or transfer into any Software provided to ARC without giving prior
written notice to ARC and receiving written approval from ARC.  ARTICLE 4 - SERVICES  Installation, training, telephone
support, and other servicing of any of the Products (collectively, Services),
shall be provided to ARC by Chiron in accordance with the terms and conditions
set forth in Schedule 4.0 attached hereto.  14 
   ARTICLE 5 - COMPENSATION,
PAYMENTS  5.1Support.  ARC agrees to assist with the costs related
to the development and supply of the WNV Assay and other costs incurred by
Chiron and Gen-Probe under this Agreement by paying to Chiron the amounts set forth
in Schedule 5.0attached hereto for the Products and Services.  5.2Payments.  All payments shall be made as set forth in Schedule 5.0.  All payments due to Chiron hereunder shall
be paid in full by ARC in U.S. Dollars within thirty (30) calendar days of the
applicable invoice date.  In the event
of late payment, interest shall be charged at the rate of [***], as reported in the
Wall Street Journal on the date such payment was due, until the date of actual
payment, such interest to accrue daily and both before and after judgment.  Chirons invoices must be
submitted to The American National Red Cross, Shared Services Center, Post
Office Box 410500, Charlotte, North Carolina 28241-0500.  Chiron shall invoice incremental freight
charges relating to Modified Orders and Rush Orders separately.  Each invoice must
contain:  Chirons
name and address; Agreement
and purchase order number; any
applicable task or shipping instruction number; a
description of the goods or services and the dates delivered or performed; any
applicable unit prices and extensions; shipping
and payment terms; and any
additional information required by this Agreement.  5.3Books
& Records; Audit.  ARC shall
keep reasonably detailed and accurate records and books of account to enable a
determination of the amounts payable by ARC to Chiron for Reportable Results as
provided hereunder.  Upon thirty (30)
days written notice by Chiron, not more frequently than once per calendar year,
Chiron, at its cost (except as otherwise provided below in this
Section 5.3) may have such records and books of account relating solely to
Reportable Results examined at an ARC location during reasonable business hours
by an independent certified public accountant selected by Chiron for the purpose
of verifying the amounts due hereunder and engaged on payment terms reasonably
acceptable to ARC.  A copy of any final
written report provided by the independent accountant to Chiron shall be given
concurrently to ARC.  [***]  In all cases, such examination by Chiron
shall not be permitted unless [***] to which the books and records
pertain.  Where such examination results
in a finding that ARC underpaid Chiron [***], ARC  15 
   shall reimburse Chiron
for its reasonable costs and expenses in conducting such examination.  ARC and Chiron shall promptly rectify
underpayments and overpayments by repaying such amounts, together with interest
thereon accruing from and, at the rate of [***] as reported in the Wall Street
Journal on, the date such under- or overpayments [***] in the aggregate for
such Fiscal Year, until the date of actual payment.  5.4Taxes.  Chiron hereby acknowledges that ARC is a
not-for-profit, charitable corporation, exempt from the payment of sales and
use taxes and ARC shall have no tax liability on Products unless specifically
legislated by a particular state. 
Chiron is responsible for requesting and obtaining all tax exemption
numbers as required.  [***]  Notwithstanding the above, if any federal,
state, provincial, county or municipal sales or use tax, excise or similar
charge, or other tax assessment (other than that assessed against income), is
assessed or charged on the sale of the WNV Assays and Blood Screening Systems
sold to ARC by Chiron pursuant to this Agreement, it shall be paid by ARC.  ARTICLE 6 - CERTAIN AGREEMENTS  6.1WNV
Assay IND.  Gen-Probe has prepared
and submitted an Investigational New Drug Application in accordance with the
Regulations to the FDA (IND) to permit the ARC to conduct nucleic acid
amplification screening to detect the presence of the West Nile Virus using the
Products (BB-IND 10920).  Gen-Probe, or
Chiron on Gen-Probes behalf, shall notify ARC in advance and provide ARC with
a copy of any amendment to Gen-Probes IND.  6.2Protocol
IND.  ARC has prepared and submitted
an IND to the FDA for the clinical protocol and preclinical studies to be
undertaken in connection with the screening of blood, plasma, other blood
components and tissue and organ samples using the Products, which application
shall cover the donor, product, and recipient management (BB-IND 11036).  6.3ARC
Use of WNV Assays Per IND.  ARC
shall not use the Products in a manner not specifically described in the ARCs
or Gen-Probes IND protocol at any time. 
ARC shall notify Chiron in advance and provide Chiron with a copy of any
amendment to ARCs IND.  6.4Provision
of Facilities by ARC.  ARC agrees to
make available, at its sole expense and discretion, adequate facilities
(including any necessary facility improvements) and personnel necessary to
conduct the clinical trials described in ARCs IND and otherwise for use of the
Products in accordance with all applicable Regulations and Documentation.  6.5Regulatory
Compliance.  16 
   (a)ARC
shall be solely responsible for compliance with all reporting and other
regulatory requirements imposed on it by the Regulations, including, but not
limited to, 21 C.F.R. Part 812.  Upon
reasonable request of Chiron, ARC shall provide Chiron with copies of reports
to the FDA relating to the use of the Products, so long as such information
requested does not violate any Regulations or confidentiality obligations of
ARC to Third Parties.  (b)Chiron
shall be solely responsible for compliance with all reporting and other
regulatory requirements imposed on it by the Regulations, including, but not
limited to, 21 C.F.R. Part 812.  Upon
reasonable request of ARC, Chiron shall provide ARC with copies of reports to
the FDA relating to the use of the Products, so long as such information
requested does not violate any Regulations or confidentiality obligations of
Chiron to Third Parties.  (c)Gen-Probe
shall be solely responsible for, or Chiron on Gen-Probes behalf shall be solely
responsible for, Gen-Probes compliance with all reporting and other regulatory
requirements imposed on it by the Regulations, including, but not limited to,
21 C.F.R. Part 812.  Upon reasonable
request of the ARC, Gen-Probe, or Chiron on Gen-Probes behalf, shall provide
ARC with copies of reports to the FDA relating to the use of the Products, so
long as such information requested does not violate any Regulations or
confidentiality obligations of Chiron or Gen-Probe to Third Parties.  (d)Any
Party hereunder agrees to make available to the requesting Party (with
authority to provide to its Affiliates or any governmental regulatory agency)
such records as may be reasonably required in accordance with a reasonably
based legal opinion for the requesting Party to satisfy its regulatory
requirements in the United States.  (e)Each
Party agrees to provide access to their facilities and documents pertaining to
this Agreement, without any prior or written notice, to the FDA should it
require access in accordance with any FDA policy, communication, or regulation.
To the extent that the FDA requires access and is investigating Products
related to this Agreement, the Party being investigated shall give notice to
the other Party.  (f)Each
Party, and Chiron on behalf of Gen-Probe, agrees to perform, on reasonable
request of the other Party, such further acts as may be reasonably necessary or
desirable for the requesting Party to stay compliant with the Regulations;
provided that the non-  17 
   requesting Party may
disagree or deny such request if such Party deems such request to require more
than commercially reasonable efforts to satisfy the request.  6.6FDA
Approval.  Each Party, and Chiron on
behalf of Gen-Probe, agrees to exercise due diligence and commercially
reasonable efforts to obtain the requisite approval from the FDA to
commercially distribute the Products during the Term.  Notwithstanding the above, if the FDA alters its recommendation
for the screening of human blood, covered and voluntary source plasma,
platelets or other blood products intended for transfusion or other
administration to humans for the presence of the West Nile Virus to recommend
screening using a Multi-Flavivirus Assay, then the obligation of the parties to
seek FDA approval to commercially distribute the Products shall be suspended
and ARC and Chiron shall meet and confer regarding the development of a
Multi-Flavivirus Assay, including without limitation, the discriminatory assays
relating thereto.  6.7Data.   ARC shall provide to Chiron and, at
Chirons request and direction, to Gen-Probe, in an agreed format data
generated in connection with the use of the Products as required for proper
submission of the Gen-Probe IND and otherwise as is sufficient to monitor the
performance of the Products for quality assurance and to perform their
respective regulatory obligations in the Territory (collectively the Data).  Each Party shall have the right to disclose,
and as to Chiron, to have Gen-Probe disclose, such data to the FDA in support
of the IND without prior written consent of the other Party.  The Data shall be deemed confidential
information of ARC.  (a)Each
Party acknowledges the other partys interest in disclosing or publishing, in
oral or written form, certain information related to ARCs use of the Products
to obtain recognition within the scientific community, to advance the state of
scientific knowledge and for marketing purposes.  Each Party also recognizes the other Partys interest in
preserving the confidentiality of certain information.  Therefore, neither party will publish any
information relating to use of the Products, including Data each Party
generates during clinical trials, without the express written consent of the
other Party, which consent shall not be unreasonably withheld.  A Party wishing to publish shall provide a
copy of the draft publication and provide the other Party not less than thirty
(30) to review and comment prior to publication.  Any such publication shall appropriately acknowledge the
contributions of the other Party.  At
the request of either Party, the Parties shall reasonably consider joint
publications.  (b)Chiron,
and on behalf of its Affiliates or Gen-Probe, shall have the right to request
use of Data in connection with other regulatory applications, submissions and
notifications, in any country, with  18 
   respect to the Products,
Blood Screening Systems or related products.  (c)The
Parties acknowledge and agree that nothing in this Agreement or otherwise will
require ARC to disclose to Chiron patient-specific, or donor or recipient
identifying information (including information that could identify a group of
donors, recipients or their geographical location), unless and to the extent
that such information is required by any applicable law, regulation or court
order.  In such event, (i) Chiron must
provide notice to ARC in writing immediately on becoming aware of such a
requirement so that ARC has an opportunity to seek a protective order or other
remedy; and (ii) ARC shall provide the required identifying information to the
extent it has such information, subject to the terms of such protective order
or other remedy.  6.8Confidentiality.   During the Term of this Agreement and [***],
absent the consent of the other Party, (i) ARC agrees to keep in confidence and
not to disclose to any Third Party other than its Affiliates, agents or
contractors who need to know in connection with ARC activities under this
Agreement, or use for any purpose, except pursuant to, and in order to carry
out, the terms and objectives of this Agreement, any Confidential Information
of Chiron, including Confidential Information of Gen-Probe which is disclosed
to ARC by or through Chiron; and (ii) Chiron agrees to keep in confidence and
not to disclose to any Third Party other than Gen-Probe and their respective
Affiliates, agents or contractors who need to know in connection with Chiron
activities under this Agreement, or use for any purpose, except pursuant to,
and in order to carry out, the terms and objectives of this Agreement, any
Confidential Information of ARC.  
Disclosures of Confidential Information to Third Parties authorized hereunder
shall be permitted only if the Third Party is bound by confidentiality
obligations not less restrictive than those set forth herein.  (a)Subject
to this Section 6.8 and except as required by a court order issued by a
court having appropriate jurisdiction, the Parties agree not to disclose to any
Third Party any financial terms of this Agreement, or any terms of this
Agreement relating to the WNV Assays and Blood Screening Systems provided
hereunder, without the prior written consent of the non-disclosing Party;
provided, however, that the Parties may disclose the existence and general
nature of this Agreement to Third Parties.  (b)The
Parties acknowledge that a violation of this Section 6.8 may cause
irreparable harm to the non-disclosing Party for which no adequate remedy at
law exists and the Parties therefore agree that, in addition to any other
remedies available, the non-disclosing Party  19 
   shall be entitled to seek
injunctive relief to enforce the terms of this Section 6.8.  6.9Intellectual
Property; Inventions.  The provision
by Chiron to ARC of the Products hereunder includes the implied license or
sublicense under Chiron and Gen-Probe intellectual property to use the Products
in the Territory as provided herein. 
Except for such implied license to the Products, and except as
specifically set forth herein, nothing in this Agreement conveys to either
Party any rights or licenses to any intellectual property of the other
Party.  The Parties do not anticipate
that use of the Products as provided herein will result in new inventions by
ARC.   However, in the event that any
such new invention is made, solely by ARC or persons obligated to assign
inventions to ARC, arising from the use of the Products, ARC will own such
invention and ARC grants to Chiron the option to obtain a non-exclusive
worldwide license to such invention (with a right to sublicense for
manufacturing purposes only), on commercially reasonable terms to be negotiated
by the Parties in good faith.  If an
invention is made jointly by ARC or persons obligated to assign inventions to
it, and Chiron or persons obligated to assign inventions to it, such invention
will be owned jointly by the Parties. 
All inventions made solely by Chiron or persons obligated to assign
inventions to it will be owned by Chiron.  6.10Inventory
Levels.  Chiron shall, at no cost to
ARC, assist each NTL monthly in managing its inventory, as well as actual
Product usage versus the Product Requirement Forecasts.  6.11Technical
and Operational Reviews.  From time
to time, Chiron shall conduct technical and operational reviews with ARC of the
Products and other Services provided by Chiron, as well as Agreement
performance, at each Partys respective expense.  The Parties shall mutually agree upon the scheduling and
locations of such reviews.  6.12Clinical
Monitor Fees.  In consideration of
ARCs allocation of resources, facilities and Data pursuant to this Agreement,
Chiron shall pay ARC [***] for such amount from ARC, to offset
those costs incurred by ARC from the engagement of Medical Marketing
Consultants in connection with monitoring of Products pursuant to the existing
IND applications (BB-IND 10920 and BB-IND 11036 for each of Gen-Probe and ARC,
respectively).  ARTICLE 7 - REPRESENTATIONS & WARRANTIES; WARRANTY
DISCLAIMER; INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE  7.1Chiron
Representations & Warranties. Chiron hereby represents, warrants and
covenants to ARC that:  20 
   (a)All
Products and Services provided pursuant to this Agreement shall conform to the
Regulations, including, but not limited to, 21 C.F.R. Part 812.  (b)[***]  (c)(i)
Chiron is duly organized, validly existing and in good standing under the laws
of the jurisdiction in which it was organized, (ii) this Agreement, when
executed and delivered by Chiron, will be the legal, valid and binding
obligation of Chiron, enforceable against Chiron in accordance with its terms,
(iii) the execution, delivery and performance of this Agreement by Chiron does
not and will not (1) conflict with, or constitute a breach or default under,
Chirons organizational documents or any material agreement, contract,
commitment, or instrument to which Chiron is a party or (2) require the
consent, approval or authorization of, or notice, declaration, filing or
registration with, any Third Party or any governmental or regulatory authority,
and (iv) Chiron has not previously granted and will not grant any rights to any
Third Party which are, nor has contracted or will contract with any Third Party
in any manner which is, inconsistent with the rights granted herein.  (d)There
are no FDA proceedings or other regulatory actions pending, threatened (orally
or in writing) or probable of assertion against Chiron or any employee, agent
or subcontractor thereof for violations of any requirements of the United
States Food, Drug and Cosmetic Act, the Public Health Service Act and/or
accompanying regulations, or any other Regulations, which would prohibit or
limit the provision of the Products as set forth in this Agreement.  (e)Chiron
has commercial insurance necessary to conform with the terms and conditions of
this Agreement and all Chiron commercial insurance shall be and remain in full
force and effect during the Term of this Agreement.  In no event shall any ARC Indemnitees recovery for Damages
assumed by Chiron be limited to the amount of the insurance limits requested.  7.2ARC
Representations & Warranties. ARC hereby represents, warrants and
covenants that:  (a)ARC
shall not make any warranty or representation, either express or implied, with
respect to any Product, which differs from any warranty or representation made
by Chiron or the applicable manufacturer in the applicable Documentation for
the Product.  21 
   (b)ARC
shall store, handle and use the Products in its control in conformity with the
Package Insert and shall comply with all Regulations applicable to the use of
such Products.  (c)(i)
ARC is a not for profit corporation chartered by an act of Congress, 36 U.S.C.
§ 30010 et  seq.,and has the full and unrestricted corporate
power and authority to execute and deliver this Agreement and to carry out the
transactions contemplated hereby, (ii) this Agreement, when executed and
delivered by ARC, will be the legal, valid and binding obligation of ARC,
enforceable against ARC in accordance with its terms, and (iii) the execution,
delivery and performance of this Agreement by ARC does not and will not (1)
conflict with, or constitute a breach or default under, ARCs organizational
documents or any material agreement, contract, commitment, or instrument to
which ARC is a party or (2) require the consent, approval or authorization of,
or notice, declaration, filing or registration with, any Third Party or any
governmental or regulatory authority that is material to ARCs ability to
carryout the transactions contemplated hereby.  (d)ARC
has commercial insurance necessary to conform with the terms and conditions of
this Agreement and all ARC commercial insurance shall be and remain in full
force and effect during the Term of this Agreement.  In no event shall any Chiron Indemnitees recovery for Damages
assumed by ARC be limited to the amount of the insurance limits requested.  7.3Limitation
of Warranty.  Chiron is not the
manufacturer of the WNV Assays provided to ARC under this Agreement.  Further, the WNV Assays are not licensed by
the FDA or any other regulatory body for use in the screening and release of
blood, plasma or other blood components and are development stage products,
provided to ARC pursuant to an IND submitted to the FDA.  EXCEPT AS EXPRESSLY PROVIDED ELSEWHERE IN
THIS AGREEMENT, CHIRON MAKES NO WARRANTIES OF ANY KIND AS TO THE PRODUCTS
PROVIDED HEREUNDER, EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING WITHOUT
LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE.  7.4Pass-Through
Warranty.  With no further act
required by ARC, Chiron agrees to pass through to ARC the benefit of
Gen-Probes manufacturer warranties with respect to each of the Products, and
Chiron with respect to any other Third Party manufacturers shall also pass
through to ARC the benefit of any manufacturers warranties with respect to
each of the Products, to the extent it is legally permitted to so by the
applicable Third Party manufacturers.  22 
   7.5Indemnity
by Chiron.  Chiron agrees to
protect, defend, indemnify and hold harmless ARC, the NTLs and all ARC units,
including without limitation, all ARC chapters and other operating units, and
their respective officers, directors, governors, employees, Affiliates,
assigns, successors, and agents (collectively, the ARC Indemnitees) and agrees
to hold them harmless from and against all Damages arising from the negligence
or willful misconduct of any of the Chiron Indemnitees or Gen-Probe in the
performance of Chirons or Gen-Probes obligations under this Agreement,
including without limitation:  (a)any
breach or violation by Chiron, Gen-Probe or any Chiron Indemnitee of any of the
applicable Regulations related to Chirons or Gen-Probes performance under
this Agreement;  (b)Chirons
provision of any Services pursuant to this Agreement;  (c)[***];
or  (d)loss
or damage to any of Chirons or any Chiron Indemnitees property, real or
personal, while performing Chirons or Gen-Probes respective obligations
pursuant to this Agreement;  provided,
that in all of the above cases Chirons indemnification responsibilities
to ARC Indemnitees shall be reduced to the extent that any of such Damages
claimed by any ARC Indemnitee results from the willful misconduct, negligence
or omission of ARC or any ARC Indemnitee or ARCs breach of its
representations, warranties, covenants or other agreements and obligations
provided in this Agreement.  7.6Indemnity
by ARC.  ARC agrees to protect,
defend, indemnify and hold harmless Chiron and its Affiliates, and their
respective officers, directors, employees, assigns, successors, contractors,
subcontractors, suppliers and agents (collectively, the Chiron Indemnitees) and
agrees to hold them harmless from and against all Damages arising from the
negligence or willful misconduct of any of the ARC Indemnitees in the
performance of ARCs obligations under this Agreement, including without
limitation:  (a)any
breach or violation by ARC or any ARC Indemnitee of any of the applicable
Regulations related to ARCs performance under this Agreement;  (b)any
use of the Products by ARC or any ARC Indemnitee other than in accordance with
the Package Insert and/or Documentation for such Products; or  23 
   (c)loss
or damage to any of ARCs or any ARC Indemnitees property, real or personal, while
performing their respective obligations pursuant to this Agreement;  provided,
that in all of the above cases ARCs indemnification responsibilities
will be reduced to the extent that any of such Damages claimed by any Chiron
Indemnitee results from the willful misconduct, negligence or omission of
Chiron or any Chiron Indemnitee or Chirons breach of its representations,
warranties, covenants or other agreements and obligations provided in this
Agreement.  7.7IP
Infringement Indemnity.  (a)In
addition to Chirons indemnification obligations set forth herein, Chiron, at
its own expense, will defend and indemnify ARC from any Damages from any suit
or claim which may be brought against any ARC Indemnitee for the infringement,
misappropriation or other violation of any Third Partys patent(s),
trademark(s), copyright(s), trade secret(s), moral right(s), semi-conductor
chip protection, proprietary information, confidential information or other
proprietary right (IP Claim) resulting from ARCs use of any
of the Products, and in such suit Chiron will satisfy any final judgment or
award for any such infringement, misappropriation or other violation.  (b)Notwithstanding
the foregoing, Chiron shall have no liability hereunder to the extent that the
IP Claim arises from or is attributable to (i) the use of the Products in
combination with other products or materials not provided by Chiron hereunder;
(ii) part (or all) of the Products being used for a purpose other than that
indicated by this Agreement; or (iii) use of the Products other than in
accordance with the Documentation provided by Chiron to ARC.  Chirons obligation to indemnify shall be
subject to ARC promptly notifying Chiron in writing of such claim and providing
reasonable cooperation to Chiron in the defense of such claim or proceeding.  (c)If,
in Chirons opinion, a Product furnished hereunder is likely to or does become
the subject of any IP Claim, then without diminishing Chirons obligation to
satisfy any final judgment or award, Chiron may, at its option, substitute for
that Product a modified version thereof that is satisfactory to ARC or, at
Chirons option and expense, obtain the right for ARC and the NTLs to continue
using the Product.  If the use of such
Product by ARC or the NTLs shall be prevented by permanent injunction, or
Chiron is unable to procure the right for ARC and the NTLs to continue using
such Product at a reasonable cost, ARC may terminate this Agreement as to the
affected Product and upon such termination, Chiron shall  24 
   accept the return of the
remaining unused affected WNV Assays and refund the amount paid Chiron for such
unused WNV Assays and/or accept the return of the affected Blood Screening
Systems.  Chiron shall also reimburse
ARC for any shipping charges paid by ARC to return the Products to Chiron and
bear all risk of loss during shipment.  7.8Indemnification
Procedures.  Any ARC Indemnitee or
Chiron Indemnitee claiming indemnification (the Indemnitee) shall notify the
Party from which indemnification is claimed (the Indemnifying Party) in
writing promptly upon becoming aware of any claim to which such indemnification
may apply.  Failure to provide such
notice shall constitute a waiver of the Indemnifying Partys indemnity
obligations hereunder if, and only to the extent that, the Indemnifying Party
is materially damaged thereby.  The
Indemnifying Party shall have the right to assume and control the defense of
the claim at its own expense.  If the
right to assume and have sole control of the defense is exercised, the
Indemnitee shall have the right to participate in, but not to control, such
defense at its own expense.  If the
Indemnifying Party does not assume the defense of the claim, the Indemnitee may
defend the claim at the Indemnifying Partys expense.  The Indemnitee will not settle or compromise the claim without
the prior written consent of the Indemnifying Party, and the Indemnifying Party
will not settle or compromise the claim in any manner which would have an
adverse effect of the Indemnitee without the consent of Indemnitee, which
consent, in each case, will not be unreasonably withheld.  The Indemnitee shall reasonably cooperate
with the Indemnifying Party and will make available to the Indemnifying Party
all pertinent information under the control of the Indemnitee.  7.9Exclusion
of Consequential Damages; Limitation of Liability.  Unless recovery for such damages is
otherwise expressly provided for in this Agreement, neither Party shall be
liable with respect to the subject matter of this Agreement under breach of
contract, negligence, strict liability or any other cause of action for any
consequential, incidental or indirect loss or damage (whether arising directly
or indirectly from a breach of this Agreement), including loss of profit or for
any cost of procurement of substitute goods, technology or services, except to
the extent of liability to Third Parties for bodily injury or death as to which
each of the Parties are obligated to indemnify each other under Sections 7.5
and 7.6, respectively.  Notwithstanding
any provision herein to the contrary, in no event shall Chiron be liable to ARC
with respect to the subject matter of this Agreement under breach of contract,
negligence, strict liability or any other cause of action in an aggregate that
exceeds the total amount paid by ARC to Chiron hereunder, except to the extent
of liability to Third Parties for bodily injury or death as to which Chiron is
obligated to indemnify ARC under Section 7.5.  25 
   7.10Insurance.  Chiron and ARC agree to maintain insurance
as follows:  (a)Insurance
Required of Chiron.  Chiron shall
maintain at its sole cost and expense the following insurance coverages in full
force and effect for the Term of this Agreement [***]:  (i)A
Commercial General Liability policy with each ARC Indemnitee named as an
additional insured as their interests may appear as respects this Agreement,
and the amount of the policy will be at least [***] combined single limit
for each occurrence and in the aggregate for each policy term;  (ii)A
Products Liability policy applicable to the design, manufacture, production and
recall of any Product supplied to ARC under this Agreement with at least [***]
for each occurrence and in the aggregate and naming each ARC Indemnitee as an
additional insured as their interests may appear with respect to this
Agreement;  (iii)A
Commercial Auto Liability policy including owned and non-owned and hired
vehicles with at least [***] in coverage with each ARC Indemnitee
named as an additional insured as their interests may appear as respects this
Agreement;  (iv)Workers
Compensation coverage with statutory limits for each jurisdiction where the
work required under this Agreement is performed;  (v)An
employers liability policy with at least the following limits: [***]
per accident, [***] per disease, and [***] disease (each employee); and  (vi)All
Risk property insurance policy at full replacement cost on all facilities,
property and equipment used in manufacturing the Products.  Chiron shall also maintain an All Risk
transit insurance policy at full replacement cost insuring all Products while
being shipped to or from ARC.  (b)Insurance
Required of ARC.  ARC shall maintain
at its sole cost and expense the following insurance coverages in full force
and effect for the Term of this Agreement [***]:  (i)A
Commercial General Liability policy with each Chiron Indemnitee named as an
additional insured as their interests may appear as respects this Agreement,
and the amount of  26 
   the policy will be at
least [***]
combined single limit for each occurrence and in the aggregate for each policy
term;  (ii)A
Professional Liability (Errors and Omissions) policy in an amount not less than
[***]
each claim and in the aggregate;  (iii)A
Commercial Auto Liability policy including owned and non-owned and hired
vehicles with at least [***] in coverage with each Chiron
Indemnitee named as an additional insured as their interests may appear as
respects this Agreement;  (iv)Workers
Compensation coverage with statutory limits for each jurisdiction where the
work required under this Agreement is performed;  (v)An
employers liability policy with at least the following limits: [***]
per accident, [***] per disease, and [***] disease (each employee);  (vi)All
Risk property insurance policy at full replacement cost on all facilities,
property and equipment used in connection with the Products, other than such
facilities, property and equipment for which this Agreement requires the
provision of insurance by Chiron.  (c)All
liability policies will be written as primary coverage and not contributing
with, or in excess of, any coverage which the other Party shall carry with
respect to the obligations of each Party. 
All workers compensation policies shall contain a waiver of subrogation
for the benefit of the other Party, except as to [***].  All insurance required under this Agreement
that is provided through commercial carriers shall be placed with insurers
which, at the time the insurance is placed, [***].  This insurance shall be and remain in full
force and effect during the Term of this Agreement.  Each Party shall provide the other with certificates of insurance
evidencing the coverage required herein upon execution of this Agreement, and
renewal certificates on request from the other Party.  Such certificates shall provide for thirty (30) days prior
written notice to the certificate holder in the event of the non-renewal or
cancellation of the policies.  Each
Party shall provide the other with prompt written notice of (i) any material
change to the coverage, limits, terms, or conditions of any insurance below
those required herein, (ii) the exercise of the batching provision under its
catastrophic insurance coverage, whether related to any potential liabilities
under this Agreement or otherwise, or (iii) any other potential impairment of
the coverage provided under any of the  27 
   insurance policies set
forth in Section 7.10(a) or (b) above. 
All information contained within such notice shall be deemed
Confidential Information of the notifying Party.  Following delivery of such notice, the Parties will meet and
confer regarding the impact of the occurrence described in such notification on
the Parties. Each of the Parties acknowledge that during the period which the
Parties are meeting and conferring with one another, as provided in the immediately
preceding sentence, the notified Party shall refrain from submitting a notice
of termination under Section 8.2(a) on the basis of the information
provided to it pursuant to this Section 7.10(c), until at least thirty
(30) days have passed from the date the Section 7.10(c) notice was first
received.  ARTICLE 8 - TERM AND TERMINATION  8.1Term.  This Agreement shall be effective as of the
Effective Date and shall continue  [***]
(the Term),
unless terminated earlier by mutual agreement of the Parties without penalty,
or otherwise in accordance with this Agreement.  The obligations under this Agreement shall terminate and expire
without any further action by the Parties upon the expiration of the Term
unless, no less than six (6) months before the expiration of this Agreement,
the Parties mutually agree in writing to extend this Agreement.  8.2Termination
for Cause.  This Agreement may be
terminated for cause by written notice to the other Party at any time duringthe Term of this
Agreement, which termination shall be effective when such termination notice is
received in accordance with Article 13, as follows:  (a)by
either Party if the other Party fails to observe, perform or otherwise
materially breaches any of its covenants, representations, warranties, or
agreements or materially defaults in the performance of its obligations under
this Agreement, provided such breach or failure continues without cure for a
period of thirty (30) days after receipt by the other Party of an initial
written notice thereof specifying such breach or failure;  (b)by
either Party if the other Party files a petition in bankruptcy, becomes
bankrupt or insolvent or subject to the reorganization of its business for the
benefit of creditors under any law or regulation relating to bankruptcy, or a
receiver is appointed for all or substantially all of its property or assets,
or upon the making by such other Party of a composition with its creditors, or
upon the taking by such other Party of any act for the winding up of its business,
or upon any governmental authority exercising any power or authority resulting
in the expropriation or confiscation of all or substantially all of its
business and assets.  If Chiron enters
into  28 
   proceedings relating to
bankruptcy, whether voluntary or involuntary, Chiron will furnish, by certified
mail, written notification of the bankruptcy to the person identified in
Section 13.5.  The notification must
be furnished within [***] of the initiation of the bankruptcy
proceedings.  The notification must
include the date on which the petition was filed, and a list of ARC purchase
orders for which final payment has not yet been made.  This obligation remains in effect until final payment under this
Agreement;  (c)by
either Party if a Force Majeure Event prevents a Party from performing its
obligations under this Agreement for a period exceeding [***], measured from the day
notice is received of the existence of such Force Majeure Event; or  (d)by
either Party if any of the Regulations are amended in a way that precludes a
Party from lawfully performing its obligations under this Agreement, effective
upon the effective date of such amended Regulation; provided, however, that [***]
prior written notice must be given by the Party intending to terminate under
this subsection and such Party shall make a good faith effort to implement
commercially reasonable strategies for compliance with any amended Regulations.  (e)by
either Party if (i) the notifying Partys institutional review board (IRB)
withdraws approval of an IND before the expiration of the Term or (ii) the FDA
revokes any approval of any of the Products or a Partys IND;  (f)[***];
or  (g)[***].  ARTICLE 9 - FORCE MAJEURE  9.1Force
Majeure.  Neither Party shall be
liable for any failure or delay in performing any of its obligations under this
Agreement to the extent that such failure or delay is due to any cause beyond
the affected Partys reasonable control, including without limitation war,
terrorism, riot, insurrection or other civil commotion, any strike, lockout or
other labor dispute, any governmental or court order, decree or regulation, any
fire, flood, epidemic, earthquake, unusually severe weather condition or other
act of God, or any freight embargo or public utility failure (a Force
Majeure Event).  (a)The
affected Party shall give prompt notice to the other Party of, and shall
exercise due diligence to eliminate or remedy all such  29 
   causes, and shall give
the other Party prompt notice when such causes have been eliminated or
remedied. Notwithstanding the foregoing, (i) a Party affected by a Force
Majeure Event shall use commercially reasonable efforts (taking into
consideration the adverse effect and duration of the Force Majeure Event) to
mitigate and ameliorate the adverse effects thereof, and (ii) the obligations
of such Party shall not be suspended pursuant to this Section 9.1 to the
extent that performance of such obligations was due before the occurrence of
the Force Majeure Event.  Further, the
affected Party shall have the burden of proving the existence, duration and
adverse effect of such Force Majeure Event.  (b)If
Chiron is the Party affected by the Force Majeure Event and such Force Majeure
Event has prevented Chiron from performing its obligations under this Agreement
for in excess of [***], [***].  ARTICLE 10 - CONSEQUENCES OF THE
TERMINATION OF THIS AGREEMENT  10.1Outstanding
Payment Obligations Unaffected.  The
termination of this Agreement for any reason whatsoever shall not affect any
Partys obligations to perform those obligations due and already accrued prior
to such termination.  In the event that
termination occurs at a time prior to ARC having made full payment that is due
and owing for any Products, the Parties agree that Chiron shall have all
applicable ownership rights to such Products until such payment has been made
in full to Chiron.  10.2Reimbursement
upon Termination.  If this Agreement
is terminated other than by mutual agreement of the Parties or for cause by ARC
pursuant to Section 8.2, then ARC shall be obligated to reimburse Chiron
for certain un-recovered costs and expenses related to the development of the
Products in an amount to be calculated in accordance with Schedule 5.0,
paragraph 2.  10.3Transition.  If the Term of this Agreement expires, upon
such expiration and for a period of no more than [***] thereafter, Chiron
shall continue to make available to ARC for purchase, at prices not to exceed [***]
of the then current prices for such quantity of Products under this Agreement,
such quantity of Products and Services as ARC deems necessary for its use in
the Blood Screening Field to facilitate an orderly transition to the
replacement service provider.  In the event of a
termination of this Agreement by ARC for any reason, Chiron shall cooperate
with ARC in the transfer of Chirons obligations hereunder to a replacement
service provider.  After receiving
notice of such termination and except as otherwise directed by ARC, Chiron
shall  30 
   continue to make
available to ARC for purchase, at prices not to exceed [***] of the then current
prices for such quantity of Products under this Agreement, such quantity of
Products and Services as ARC deems necessary for its use in the Blood Screening
Field to facilitate an orderly transition to the replacement service provider
during the time period required for such transition, not to exceed [***].  During any such
transition following expiration or termination by ARC, ARCs purchase
obligations with respect to the quantity of such Products and/or Services shall
be reduced to the extent ARC deems necessary to transition to the replacement
service provider.  10.4Survival
of Certain Provisions.  In addition,
notwithstanding anything herein to the contrary, the following provisions of
this Agreement shall survive termination of this Agreement: Sections
3.2(f)(vii), 5.3, 6.5(d), 6.7, 6.8, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, and 7.10
and Articles 10, 11, 12 and 13.  10.5Return
of Confidential Information.  Upon
termination of this Agreement for any reason whatsoever, the Parties shall
immediately return to the other all confidential information in documentary or
printed form and any copies or extracts thereof and shall thereafter cease to
use such information but without prejudice to the then surviving
confidentiality obligations provided for in Section 6.8 hereof.  10.6No Other
Payment.  No indemnity or
compensation in any formwhatsoever shall be paid by either Party
to the other in connection with a termination in accordance with the terms
hereof (subject to any liability that may exist in respect of any material
breach prior to such termination).  ARTICLE 11 - APPLICABLE LAW  This Agreement shall be
governed by and construed in accordance with the laws of the State of
California, without giving effect to any conflict of law rules and regulations.  ARTICLE 12 - DISPUTES  12.1To the
extent that there are disputes with respect to performance under this
Agreement, such disputes (other than non-payment) are not cause for Chiron to
stop performance under this Agreement, but will be resolved in due course to
the extent possible in accordance with this Article.  12.2The
Parties to this Agreement will attempt to resolve any problem or dispute
arising out of, or related to, this Agreement through good faith consultation
in the ordinary course of business.  31 
   12.3If the
Parties are unable to resolve the problem or dispute within thirty (30) days,
either Party may initiate and submit a matter through the dispute resolution
procedure set forth in Section 12.4 below.  No Party may institute litigation until the dispute resolution
procedure has been completed unless, and to the extent that, doing so is
necessary to avoid irreparable harm.  12.4Dispute
Resolution Procedure.  If any
problem or dispute arising out of or related to this Agreement is not resolved
by the Parties in the above described manner, the Parties hereby agree to
resolve such dispute by arbitration conducted in accordance with the Commercial
Arbitration Rules of the American Arbitration Association.  The place of arbitration shall be Arlington,
Virginia.  The arbitration panel shall
consist of three arbitrators, one arbitrator appointed by each of the Parties,
and the third arbitrator appointed by the two appointed arbitrators (the Panel).  The Panel may, at its discretion, provide
for discovery by the Parties not to exceed a period of sixty (60) days from the
date of filing of the notice of arbitration. 
The Panel shall render its decision within ninety (90) days from the
date of filing the notice of arbitration and may, at its discretion, award
costs and expenses but shall not have the right to award punitive damages.  The decision of the Panel shall be final and
binding on the Parties, and shall be enforceable in any court of competent
jurisdiction.  12.5The
prevailing Party shall be entitled to recover all costs and expenses, including
reasonable attorneys fees, incurred because of any legal action arising in
relation to this Agreement.  ARTICLE 13- MISCELLANEOUS  13.1National
Testing Laboratories.  The full
names and addresses of the NTLs participating in this Agreement are set forth
in Schedule 1.36, which may be modified from time to time as
determined by ARC.  Any change to the
number or location of NTLs shall be provided in writing by ARC to Chiron at
least ninety (90) days in advance of such change, wherever possible.  13.2Equal
Employment Opportunity.Neither
ARC nor Chiron will discriminate, in terms and conditions of employment,
against employees or applicants because of age, race, color, religion, sex, national
origin, qualified disability or any other basis protected by applicable state
or local law.  ARC and Chiron agree to
abide by all federal, state and local employment and labor law notice posting
requirements.  13.3Assignment.  This Agreement shall not be directly or
indirectly assigned or otherwise transferred by the Parties, nor, except as
expressly provided hereunder, may any right or obligations of either of the
Parties hereunder  32 
   be assigned or
transferred (whether voluntarily, by operation of law or otherwise) without the
prior written consent of the other Party. Either Party may assign and transfer
to an Affiliate, or any Third Party acquiring all or substantially all of the
business assets or liabilities necessary to transact business, as contemplated
hereunder, provided that (i) the assigning Party provides written notice of
such assignment at least forty-five (45) days prior to its intended
effectiveness and (ii) the assignee provides to the non-assigning Party
adequate assurances of its intent to perform under this Agreement. This
Agreement shall inure to the benefit of and be binding upon the Parties hereto
and their respective successors and permitted assigns.  13.4Subcontracting.  Chirons obligations under this contract may
not be subcontracted without the prior written consent of ARC.  Any attempt to subcontract without such
consent will be null and void and of no effect.  Chiron must require that
all subcontractors approved by ARC be bound by the terms of this Agreement and
to assume toward Chiron all obligations and responsibilities which Chiron
assumes toward ARC.  Chiron must make
available to each approved subcontractor, prior to the execution of any
subcontract agreement, a copy of this Agreement to which the subcontractor will
be bound.  For purposes of any
subcontracts entered into pursuant to this Section 13.4, the term Chiron
as used in this Agreement, will include any and all ARC-approved
subcontractors.  Each subcontract agreement
must preserve and protect the rights of ARC with respect to the goods or
services provided by Chiron.  The
subcontractor must enter into similar agreements with all sub-subcontractors.  ARC retains the unrestricted right to review
all subcontract agreements, or other documents pertaining to the retention of
any subcontractor at any tier, for performance under this Agreement, prior to
the execution of such subcontract or other agreement.  Upon ARC approval, each subcontract agreement shall be assigned
by Chiron to ARC; provided, however that assignment shall only be effective in
the event Chiron terminates a subcontracting agreement with a subcontractor and
ARC accepts such assignment by notifying the subcontractor in writing.  Chiron must expressly provide for such
assignment in all of its subcontract agreements.  Chiron must require each
ARC-approved subcontractor, if any, to procure and maintain insurance of the
types and amounts required of Chiron in favor of ARC.  In addition, the subcontractors must assume indemnification
responsibilities identical to those provisions agreed to by Chiron and
contained in this Agreement, in favor of ARC.  33 
   Chiron agrees to include
in all subcontracts entered into under this Agreement a provision to the effect
that ARC and its authorized representatives will, until [***] after final payment
under the subcontract, or for any shorter period specified by law for
particular records, have access to and the right to examine any books,
documents, papers, or other records of the subcontractor relating to the
subcontract.  Nothing in this Agreement
will be deemed to entitle subcontractors, materialmen, or lower-tier
subcontractors rights as Third Party beneficiaries of this Agreement between
ARC and Chiron.  Notwithstanding any
statement to the contrary, Chiron will at all times be responsible for all acts
and/or omissions of its subcontractors.  13.5Notices.  Any Notice or request required or permitted
to be given in connection with this Agreement shall be deemed to have been
sufficiently given if sent by (i) pre-paid registered or certified mail, return
receipt requested, or (ii) hand-delivered by a nationally recognized courier,
to the address set forth below or to such other address as may have been
notified in writing.  If to Chiron:
  
  Chiron CorporationAttention:  President, Blood Testing4560 Horton StreetEmeryville,
  California  94608Phone: [***]With a copy to:
  
  General CounselIf to ARC:
  
  American National Red
  CrossAttention: Vice
  President, NTRL13504 South Point
  BoulevardCharlotte, North
  Carolina 28273Phone: [***]With a copy to:
  
  The American National
  Red Cross(which shall not
  
  Attention: Office of
  the General Counselconstitute notice)
  
  2025 E Street, NWWashington, DC
  20006-5009Phone:  [***]  A notice, consent,
approval or other communication takes effect from the time it is received
unless a later time is specified in it, and receipt shall be deemed to occur as
follows:  (a)If
it is sent by mail, seven (7) calendar days after posting; and  34 
   (b)If
it is sent by courier, on the date and at the time shown on the couriers
standard written confirmation of receipt.  13.6Entire
Agreement.  This Agreement
constitutes the entire agreement between the Parties in respect of the subject
matter hereof.  This Agreement cancels
and supersedes any and all pre-existing agreements, either oral or in writing
between the Parties.  There are not and
shall not be any oral statements, representations, warranties, undertakings or
agreements between the Parties other than as provided by this Agreement and any
mutually accepted written amendments or letter agreements attached hereto.  This Agreement may not be amended, altered or
modified except by a written document executed by all of the Parties hereto.  13.7Order
of Precedence; Conflict Between Terms and Conditions.  In the event of a conflict between the terms
of this Agreement and any other document related hereto, the terms of this
Agreement shall govern.  Unless
otherwise explicitly stated in this Agreement, in the event of any conflict
between the terms of this Agreement and the terms of any of the Schedules or
Exhibits hereto, or the terms and conditions of this Agreement and any terms
and conditions that may be set forth in any order, invoice, verbal agreement or
otherwise, the terms and conditions of this Agreement shall control and govern
any interpretative efforts.  13.8Interpretation.  This Agreement shall be construed as if both
Parties drafted it jointly, and shall not be construed against either Party as
principal drafter.  13.9No
Waiver.  The failure on the part of
either Party hereto to exercise or enforce any right conferred upon it by this
Agreement shall not be a waiver of any such right nor shall any single or
partial exercise of any right or power hereunder or further exercise thereof
operate so as to bar the later exercise or enforcement thereof.  13.10Nature of
Relationship; Independent Contractor. 
Nothing herein contained shall be deemed to be or construed as
constituting either Party the agent or partner of the other Party.  The relationship between ARC and Chiron shall
be that of an independent contractor.  No Party shall have the right, title or authority to enter into
any contract, agreement or commitment on behalf of the other or to bind the
other Party in any manner whatsoever.  13.11Compliance
with Applicable Law.  In performing
this Agreement, the Parties shall comply with all applicable laws and
Regulations.  Nothing in this Agreement
shall be construed so as to require the violation of law, and wherever there is
any conflict between any provision of this Agreement and any rule of mandatory
law, the latter shall prevail, but in  35 
   such event, the affected
provision of this Agreement shall be ineffective only to the extent necessary
to comply with the applicable law, the remainder of this Agreement shall remain
in full force and effect, and the Parties hereto undertake to replace the
invalid and/or unenforceable provision by a valid and/or enforceable provision,
the nature and scope of which will come as close as possible to the contractual
provision to be replaced, taking into account the economic intentions and
business purposes of the Parties.  13.12Publicity.
Neither Party shall permit or generate any publicity, advertising or promotion
concerning this Agreement without the prior written consent of the other
Party.  Each Party recognizes that the
name, logo and marks of the other Party represent valuable assets of that Party
and that substantial recognition and goodwill are associated with such assets.  Each Party hereby agrees that neither it nor
any of its Affiliates shall use the other Partys name, logo or marks without
the prior written authorization from such other Party.  Each of the Parties
acknowledges that a violation of this Section 13.12 would cause
irreparable harm to the other Party for which no adequate remedy at law exists
and each Party therefore agrees that, in addition to any other remedies
available, and notwithstanding any other provision of this Agreement, the
aggrieved Party shall be entitled to injunctive relief to enforce the terms of
this Section 13.12.  To the extent
allowed by law, the prevailing Party shall be entitled to recover all costs and
expenses, including reasonable attorneys fees, incurred because of any legal
action arising in relation to this Section 13.12.  13.13Disclosure
of Agreements and Terms.  Subject to
mutual agreement as to form and substance, each of the Parties may issue a
press release disclosing the existence of this Agreement.  Each Party may disclose any of the terms of
this Agreement to any Affiliate; provided that the recipient of such disclosure
is obligated to confidentiality terms no less restrictive than those contained
in Section 6.8.  Each Party may
disclose any information contained in or regarding this Agreement to the extent
required in its respective reasonable judgment by applicable law, regulation or
order of any court or governmental agency. 
Further, each Party may determine in its respective discretion to file
this Agreement under the Securities and Exchange Act of 1934, even if that
filing may result in this Agreement becoming available to the public
generally.  The filing Party shall seek
confidential treatment for at least the essential financial terms hereof in
connection with any such filing, subject to applicable law and regulation, and
shall notify the other Party in advance of any such filing and consider such
suggestions as the other Party may make as to the terms herein as to which the
filing party should seek confidential treatment.  36 
   13.14Counterparts.  This Agreement may be executed in two or
more counterparts, each of which shall be deemed to be an original and each of
which shall constitute one and the same Agreement.  [Remainder of page intentionally left blank]  [Signature pages follow.]  37 
   IN WITNESS WHEREOF, the
Parties hereto, through their authorized representatives, have set their hands
as of the date first abovewritten, whereby they evidence their
intent to be legally bound to this Agreement.  CHIRON CORPORATION
  THE AMERICAN NATIONAL RED CROSSBy:
  /s/ Jack Goldstein
  
  By:
  /s/ Robert H. Kloak forName:
  Jack Goldstein
  Name:
  Richard PlatteTitle:
  President, Chiron Blood Testing
  Title:
  Vice President, National Testing &Reference LaboratoriesBy:
  /s/ Philip YenrickName:
  Phil Yenrick  10-14-03Title:
  Director, National
  Contracting Office  38 
   Schedule 1.26  NTLs  1.Charlotte 13500 South Point Blvd. Charlotte, NC  28273  2.Detroit 100 Eliot Street Detroit, MI  48201  3.Philadelphia 700 Spring Garden Street Philadelphia, PA  19123  4.St.
Louis 4050 Lindell Blvd. St. Louis, MO  63108  5.Southern
CA 8885 Rehco Road San Diego, CA  92121  39 
    Schedule 2.0  WNV ASSAY  [Package Insert to
be attached]  40 
   Procleix®WNV Assay  For
Investigational Use Only. The
performance characteristics of this product have not 
been established. 5000
Test Kit  TABLE OF CONTENTSINTENDED
  USE
  
  1SUMMARY AND
  EXPLANATION OF THE TEST
  
  1PRINCIPLES OF THE PROCEDURE
  
  1MATERIALS PROVIDED
  
  2MATERIALS
  REQUIRED, SOLD SEPARATELY
  
  2MATERIALS
  REQUIRED BUT NOT PROVIDED
  
  2REAGENTS
  
  2STORAGE INSTRUCTIONS
  
  3PRECAUTIONS
  
  4REAGENT PREPARATION
  
  4SPECIMEN
  COLLECTION, STORAGE, AND HANDLING
  
  5PROCEDURAL NOTES
  
  5INSTRUCTIONS FOR USE
  
  7Target Capture
  
  7Amplification
  
  8Hybridization
  Protection Assay (HPA)
  
  8QUALITY CONTROL PROCEDURES
  
  9Acceptance Criteria for the
  Procleix WNV Assay
  
  9Acceptance
  Criteria for the Calibration and Calculation of Cutoff
  
  9INTERPRETATION OF RESULTS
  
  10LIMITATIONS OF THE
  PROCEDURE
  
  11BIBLIOGRAPHY
  
  11   INTENDED
USE  The Procleix®
WNV Assay* is a qualitative in vitro
nucleic acid amplification test for the detection of West Nile virus (WNV) RNA
in human plasma from volunteer donations of whole blood and blood components
for transfusion, and source plasma for further manufacturing, and from tissue
and organ donations.  The assay is
intended for use in screening individual donor samples or pools of human plasma
comprised of equal aliquots of not more than 16 individual donations.  SUMMARY AND EXPLANATION OF THE TEST  WNV is a mosquito-borne
flavivirus that is associated with human disease ranging from mild flu-like
symptoms to severe neurological disease(1),(2).  Most WNV infections are asymptomatic and approximately 20% lead
to a mild illness known as West Nile virus fever.  Less than 1% of infections are estimated to cause serious
neurological disease, with advanced age being the most significant risk
factor(3).  Prior to an outbreak in Queens
New York in 1999, the presence of the virus in North America had not been
documented.  Since the original New York
outbreak, the virus, which is carried predominantly by the Culex, sp. of mosquitoes, has continued to
expand westward and is now thought to be permanently established in North
America(4).  A large number of avian
species serve as a reservoir host for the virus, whereas humans and animals,
such as horses and other mammals, are believed to be incidental hosts(5).  As of January 2003,
the CDC reported nearly 4000 confirmed human WNV positive cases and 259 human
fatalities in the US.  The principal
route of human WNV infection is through the bite of an infected mosquito.  In 2002, new mechanisms of person-to-person
transmission were documented, including possible mother to infant infection
through breast milk, transplacental infection, and transmission through organ
donation and blood transfusion.  As of
January 2003, fourteen cases of transfusion associated transmission of WNV
were confirmed(6),(7).  In most human infections,
WNV multiplies to a relatively low level producing a transient viremia that can
be detected in whole blood and plasma. 
Nucleic acid testing (NAT) methods are capable of detecting infection
prior to the presence of antibodies during the viremic phase.  Immunoglobulin M (IgM) antibody can be
detected in serum or cerebrospinal fluid (CSF) collected within 8 days of
illness onset.  The IgM and the T memory
cells can remain in the body for years(3),(5). 
Current methods for the diagnosis of WNV are IgM enzyme immunoassay,
Plaque Reduction Neutralization assays, and NAT methods.  Because the serologically based assays
detect host immune response after the primary viremic phase, they may not be
appropriate for blood screening.  Screening of whole blood
donations with NAT has been in place in the United States since early 1999 and
licenses were granted for HIV-1 and HCV screening in 2002.  The Procleix WNV Assay, uses the same
technology as the Procleix HIV-1/HCV Assay to detect WNV RNA(8).  PRINCIPLES OF THE PROCEDURE  The Procleix®
WNV Assay involves three main steps which take place in a single tube:  sample preparation; WNV RNA target
amplification by Transcription-Mediated Amplification (TMA)(9); and detection
of the amplification products (amplicon) by the Hybridization Protection Assay
(HPA)(10).  During sample
preparation, RNA is isolated from plasma specimens via the use of target
capture.  Plasma is treated with a
detergent to solubilize the viral envelope, denature proteins and release viral
genomic RNA.  Oligonucleotides (capture
oligonucleotides) that are homologous to highly conserved regions of WNV, are
hybridized to the WNV RNA target, if present, in the test specimen.  The hybridized target is then captured onto
magnetic microparticles that are separated from plasma in a magnetic
field.  Wash steps are utilized to
remove extraneous plasma components from the reaction tube.  Magnetic separation and wash steps are
performed with the Chiron Procleix TCS.  Target amplification
occurs via TMA, which is a transcription-based nucleic acid amplification
method that utilizes two enzymes, MMLV reverse transcriptase and T7 RNA
polymerase.  The reverse transcriptase
is used to generate a DNA copy (containing a promoter sequence for T7 RNA
polymerase) of the target RNA sequence. 
T7 RNA polymerase produces multiple copies of RNA amplicon from the DNA
copy template.  The Procleix WNV Assay
utilizes the TMA method to amplify regions of WNV RNA.  Detection is achieved by
HPA using single-stranded nucleic acid probes with chemiluminescent labels that
are complementary to the amplicon.  The
labeled nucleic acid probes hybridize specifically to the amplicon.  The Selection Reagent differentiates between
hybridized and unhybridized probes by inactivating the label on unhybridized
probes.  During the  
 *Developed and
manufactured by Gen-Probe Incorporated; distributed by Chiron Corporation.  1 
   detection step, the
chemiluminescent signal produced by the hybridized probe is measured in a
luminometer and is reported as Relative Light Units (RLU).  Internal Control is added
to each test specimen, external quality control (if used), assay calibrator,
and blank tube via the Target Capture Reagent that contains the Internal
Control.  The Internal Control in this
reagent controls for specimen processing, amplification and detection
steps.  Internal Control signal in each
tube or assay reaction is discriminated from the WNV signal by the differential
kinetics of light emission from probes with different labels(11).  Internal Control-specific amplicon is
detected using a probe with rapid emission of light (flasher signal).  Amplicon specific to WNV is detected using
probes with relatively slower kinetics of light emission (glower signal).  The Dual Kinetic Assay (DKA) is a method
used to differentiate between the signals from flasher and glower
labels(11).  When used for the detection
of WNV, the Procleix WNV Assay differentiates between Internal Control and WNV
signals.  MATERIALS PROVIDEDProcleix®
  WNV Assay
  
  5000 Test Kit P/N
  301135Internal
  Control ReagentTarget
  Capture ReagentAmplification
  ReagentEnzyme
  ReagentProbe
  ReagentSelection
  ReagentNegative
  CalibratorPositive
  CalibratorBlank  MATERIALS REQUIRED, SOLD SEPARATELY  Procleix®
  Assay Fluids
  
  P/N 301027Wash
  SolutionOilBuffer
  for Deactivation FluidProcleix®
  Auto Detect Reagents
  
  P/N 301121Auto
  Detect 1Auto
  Detect 2Disposables(Disposables
  are single use only, do not reuse. Use of other disposables is not
  recommended.)Ten-Tube
  Units (TTUs)
  
  P/N TU0040Ten
  Tip Cassettes
  
  P/N 104578Sealing
  Cards
  
  P/N 102085Procleix®
  WNV
  Assay Calibrators and Blank
  
  P/N 301151Positive
  CalibratorNegative
  CalibratorBlankProcleix®
  WNV
  Proficiency Panels
  
  P/N 301152Positive
  Panel MembersNegative
  Panel Members  Chiron CPT (Correlated Pipetting Transfer) Pooling Software
(Only required for pooling)  The Chiron® CPT Pooling Software, used in
combination with the TECAN GENESIS RSP, performs sample scanning and pooling
operations that combine aliquots from individual samples into a single Master
Pool Tube, which may be used for further testing.  Equipment  Procleix® System (available from Chiron
Corporation)  Dedicated fixed or
adjustable repeat pipettor capable of delivering 400 μL of Target Capture
Reagent with a ± 5% accuracy and a precision of < 5% CV. (Only
required for manual sample pipetting method.)  Dedicated single channel
pipettor capable of delivering 500 μl of specimen with a ± 5% accuracy and a
precision of < 5% CV.(only required for manual sample pipetting
method.)  MATERIALS REQUIRED BUT NOT PROVIDED  Eppendorf COMBITIPS
repeat pipettor tips (12.5 mL, 5.0 mL, 1.25 mL) or equivalent  Disposable 1000 μL filter
tips in rack  Bleach  For use in final
concentration of 5% sodium hypochlorite and 0.5% sodium hypochlorite  Bleach alternative
(optional)  Contact Chiron Technical
Support for a list of bleach alternatives and instructions for use.  Sterile,
polypropylene conical tubes with sealing caps  Freestanding tubes are
recommended in two different sizes (5 mL to 10 mL tube and > 30 mL
tube).  The tubes must be able to
accommodate the diameter of an Eppendorf Repeat pipettor tip  TECAN GENESIS disposable
1000 μL conductive filter tips  TECAN 100 mL reagent
troughs  REAGENTS  Procleix®
WNV Assay Kit:  P/N
301135  5000 Test Kit  CONTENTS
  
  Number of vials/
  Volume per vialReagent Name
  
  5000 
  Test KitInternal
  Control Reagent
  
  10
  X 5 mLA
  HEPES buffered solution containing detergent and an RNA transcript.Store
  unopened reagent at 15°to 35°C.Target
  Capture Reagent
  
  10
  X 280 mLA
  HEPES buffered solution containing detergent, capture oligonucleotides and
  magnetic microparticles.Store
  at 2°to 8°C.  (Do not
  freeze)Internal Control Reagent must be added to Target Capture Reagent
  before use in the assay.  INO135 Rev. 1  2 
   Amplification
  Reagent
  
  15
  X 32 mLPrimers,
  dNTPs, NTPs and co-factors in TRIS buffered solution containing PROCLIN 300
  as preservative.
  Store unopened reagent  at 15°to 35°C.Enzyme
  Reagent
  
  10
  X 18 mLMMLV
  Reverse Transcriptase and T7 RNA Polymerase in HEPES/TRIS buffered solution
  containing 0.05% sodium azide as preservative.
  Store unopened reagent at 15°to 35°C.Probe
  Reagent
  
  10
  X 75 mLChemiluminescent
  oligonucleotide probes in succinate buffered solution containing detergent.
  Store unopened reagent at 15°to 35°C.Selection
  Reagent
  
  10
  X 180 mLBorate
  buffered solution containing surfactant.
  Store at 15°to 30°C.Negative
  Calibrator
  
  90
  X 2 mLA
  HEPES buffered solution containing detergent.
  Store at 15°to 35°C.Positive
  Calibrator
  
  90
  X 2 mLA
  HEPES buffered solution containing detergent and a WNV RNA transcript.
  Store at 15°to -35°C.Blank
  
  90
  X 2 mLA
  HEPES buffered solution containing detergent.
  Store at 15°to 35°C.  STORAGE INSTRUCTIONS  A.Room temperature is defined as 15°
to 30°C.  B.[GRAPHIC]
The Probe Reagent is light sensitive. 
Protect this reagent from light during storage and preparation for use.  C.Target
Capture Reagent (TCR) is stable when stored unopened at 2°
to 8°C.  If a
precipitate forms in the Target Capture Reagent during storage, see
instructions under REAGENT PREPARATION. 
DO NOT VORTEX. DO NOT FREEZE Target Capture Reagent.  NOTE:  If after removing the TCR from storage at 2°
to 8°C, the precipitate is allowed to settle to the
bottom of the container, the likelihood of the formation of a gelatinous
precipitate is increased substantially.  D.Selection
Reagent is stable when stored unopened at room temperature.  Mix thoroughly
prior to use.  E.The following reagents are stable when stored
unopened at room temperature until the expiration date. Wash Solution Oil Auto Detect 1 Auto Detect 2 Buffer for Deactivation Fluid  Do
not use after the expiration date.  Note:  These are universal fluids and may be used
with all Procleix assays.  F.Once opened, Wash Solution, Oil, Selection
Reagent, Buffer for Deactivation Fluid, Auto Detect 1 and Auto Detect 2 are
stable for 30 days when stored at room temperature.  G.The following reagents are stable when stored
unopened at -15° to -35°C. Internal
Control Reagent Amplification
Reagent Enzyme
Reagent Probe
Reagent Negative
Calibrator Positive
Calibrator Blank  H.After
thawing, the Amplification Reagent, Enzyme Reagent, Probe Reagent, are stable
when stored at 2° to 8°C for 30 days.  Once completely thawed, these reagents may
be kept at room temperature up to 8 hours per 24-hour period while in use, not
to exceed 80 hours at room temperature. 
Do not refreeze Internal Control, Amplification, Enzyme, or Probe,
Reagents after the initial thaw.  I.After
thawing, the Negative Calibrator, the Positive Calibrator, and the Blank may be
kept at room temperature up to 8 hours. 
These are single use vials and must be discarded after use.  J.After
addition of Internal Control Reagent, the working Target Capture Reagent is
stable when stored at 2° to 8°C
for 30 days and may be kept at room temperature up to 8 hours per 24-hour
period while in use, not to exceed 80 hours at room temperature.  K.If
precipitate forms in the Wash Solution, Amplification Reagent, Probe Reagent,
Negative Calibrator, Positive Calibrator or Blank warm to 15°
to 30°C and mix thoroughly prior to use.  See instructions under REAGENT
PREPARATION.  L.If
precipitate forms in the Selection Reagent during storage, see instructions
under REAGENT PREPARATION.  M.Changes
in the physical appearance of the reagent supplied may indicate instability or
deterioration of these materials.  If
changes in the physical appearance of the reagents are observed (e.g., obvious
changes in reagent color or cloudiness apparent with microbial contamination),
they should not be used.  N.The
Blank is not master lot matched and may be used with any master lot of
reagents.  INO135 Rev. 1  3 
   PRECAUTIONS  A.For
Investigational Use Only.  The
performance characteristics of this product have not been established.  B.Specimens may be infectious.  Use Universal Precautions when performing
the assay(15).  Proper handling and
disposal methods should be established according to local, state and federal
regulations(12-14).  Only personnel
qualified as proficient in the use of the Procleix® WNV Assay, the
use of the TECAN GENESIS RSP and/or manual sample/TCR pipetting, and trained in
handling infectious materials should perform this procedure.  C.Use routine laboratory precautions.  Do not pipette by mouth.  Do not eat, drink or smoke in designated
work areas.  Wear disposable gloves and
laboratory coats when handling specimens and kit reagents.  Wash hands thoroughly after handling
specimens and kit reagents.  D.To reduce the risk of invalid results,
carefully read the entire package insert for the Procleix WNV Assay and the
operators manuals for the Procleix System prior to performing an assay run.  E.Material Safety Data Sheets are available
upon request.  F.Avoid contact of Auto Detect Reagents 1 and 2
with skin, eyes and mucous membranes. 
Wash with water if contact with these reagents occurs.  If spills of these reagents occur, dilute
with water before wiping dry and follow appropriate site procedures.  G.Dispose of all materials that have come in
contact with specimens and reagents according to local, state and federal
regulations(12-13).  Thoroughly clean
and disinfect all work surfaces.  H.Use only supplied or specified required
disposables.  I.DO NOT interchange, mix, or combine reagents
from kits with different master lot numbers.  J.Avoid microbial and ribonuclease
contamination of reagents.  K.Store all assay reagents at specified
temperatures.  The performance of the
assay may be affected by use of improperly stored assay reagents.  See STORAGE INSTRUCTIONS and REAGENT
PREPARATION.  L.Do not combine any assay reagents or fluids
without specific instruction.  REAGENT PREPARATION  This step should be performed
prior to beginning Target Capture in an area that is free of template and
amplicon.  Room temperature is defined as15°to 30°C.  1.Warm
all reagents to room temperature and mix thoroughly prior to use.  A dedicated waterbath at room temperature
may be used to aid this process.  Ensure
that precipitates are dissolved.  Do not
use a reagent if precipitate or cloudiness is present.  See step 6 for Target Capture Reagent
preparation.  2.DO
NOT heat Probe Reagent, above 30°C.  3.Thaw
reagents upright.  4.If
necessary, thaw Amplification, Probe and Enzyme Reagents at room temperature or
at 2° to 8°C. Internal
Control, Amplification and Probe Reagents may be mixed by vortexing.  Enzyme Reagent should be mixed thoroughly by
gentle inversion taking care to avoid excessive foaming.  Once completely thawed, these reagents may
be kept at room temperature up to 8 hours per 24-hour period while in use.  These reagents are stable for 30 days when
stored at 2° to 8°C.  Record date of thaw (THAW DATE) for
Amplification, Probe and Enzyme Reagents in the space provided on the label.  5.Precipitate
will form in the Probe Reagent when stored at 2°
to 8°C.  Probe
Reagent may be warmed in a water bath to facilitate dissolution of precipitate,
but temperature in the bath should not exceed 30°C.  The Probe Reagent may take up to 4 hours
with periodic mixing to allow complete dissolution of precipitate if thawing is
conducted on the lab bench.  Ensure that
precipitates in the Probe Reagent are dissolved.  Do not use if precipitate or cloudiness is present.  6.Selection
Reagent is stored at room temperature. 
If Selection Reagent has been inadvertently stored at 2°
to 8°C or the temperature of the laboratory falls
below 15°C, precipitate may form.  If precipitate forms in the Selection
Reagent during storage, heat at 60° ± 1°
C for no more than 45 minutes, shaking the bottle frequently (every 5 to 10
minutes).  Once all precipitate has gone
back into solution, place the bottle in a room temperature water bath and allow
the bottle to equilibrate for at least 1 hour. 
Do not use the Selection Reagent until it has equilibrated.  The Selection Reagent must be at room
temperature before use.  Do not use if
precipitate or cloudiness is present.  7.Prepare
working Target Capture Reagent: thaw one vial of Internal Control Reagent at
room temperature or 2° to 8°C.  Mix the Internal Control Reagent thoroughly
by inversion.  Remove Target Capture
Reagent (TCR)  from 2°
to 8°C storage. 
IMMEDIATELY upon removing from storage, mix vigorously (at least 10
inversions).  DO NOT VORTEX.  After mixing, place the TCR bottle at 22°
to 30°C. 
Approximately every 10 minutes shake the bottle until all precipitate
has disappeared.  TCR precipitate should
normally dissolve in about 30 minutes. 
If a gel is observed after performing this procedure, a new bottle must
be used according to the handling recommendations above.  Return the bottle with gel back to 2°
to 8°C storage for subsequent use.  When the Internal Control Reagent and TCR
have reached room temperature, mix TCR thoroughly by inversion.  Pour the entire vial of Internal Control
Reagent into the TCR bottle.  The total
time for each of these reagents at room temperature must not exceed 8 hours, in
the first 24-hour period.  This is now
the working Target Capture Reagent.  Mix
thoroughly.  Use the space indicated on
the TCR bottle to record the date Internal Control Reagent was added and lot
number used (IC LOT).  Record the date
of manufacture of the working TCR in the space provided on the label.  8.Thaw
calibrators and Blank at room temperature. 
These are single use vials and must be thawed prior to each run.  Once thawed, use calibrators and blank
within 8 hours.  Mix thoroughly by
inversion.  9.Wash
Solution is shipped at ambient temperature and stored at room temperature.  Precipitates may form in the Wash Solution
during shipment or during storage when temperatures fall below 15°C.  Wash Solution may be incubated in a warm
water bath to facilitate dissolution of precipitate.  Temperature in the bath should not exceed 30°C.  Ensure that precipitates in  INO135 Rev. 1  4 
   the Wash Solution are dissolved prior to use.  Do not use if precipitate or cloudiness is
present.  10.Once opened, Wash Solution, Oil, Selection
Reagent, Buffer for Deactivation Fluid, Auto Detect 1 and Auto Detect 2 are
stable for 30 days when stored at room temperature.  Record the date the reagent was first opened (OPEN DATE) in the
space provided on the label.  11.To prepare Deactivation Fluid, mix one part
Buffer for Deactivation Fluid with one part 5% sodium hypochlorite.  Deactivation Fluid is stable for 30 days when stored at room temperature.  SPECIMEN COLLECTION, STORAGE AND HANDLING  NOTE:  Handle all specimens as if they are potentially infectious
agents.  Take
care to avoid cross-contamination during the sample handling steps.  For example, discard used material without
passing over open tubes.  A.Plasma collected in K2EDTA, K3EDTA,
heparin, or in Becton Dickinson EDTA Plasma Preparation Tubes (PPT) may be
used.  Follow sample tube manufacturers
instructions.  Specimen stability is
affected by elevated temperature.  Whole
blood or plasma from pooled or individual donor specimens may be stored for up
to 72 hours from time of draw at £ 25°C;
temperatures not to exceed 30°C are acceptable
for no more than 24 hours.  Specimens
may be stored an additional five days at 2°
to 8°C following centrifugation.  Plasma separated from the cells may be
stored for longer periods of time at £
-20°C before testing.  Do not freeze whole
blood.    
 *The 2-30°C
and 2-25°C periods indicated above may occur at any time.  B.Additional
specimens taken from blood or plasma units collected in ACD or sodium citrate
according to the collection container manufacturers instructions may be
used.  ACD or sodium citrate whole blood
or plasma may be stored as in A. above.  C.Additional
specimens may be taken from whole blood or plasma units containing CPD, CP2D,
or CPDA-1 anticoagulants collected according to the collection container
manufacturers instructions.  Whole
blood (not plasma units) collected in these anticoagulants may be stored for up
to 13 days at 2° to 8°C prior to
centrifugation.  At any time within this
13-day period, the whole blood unit may have been stored for up to one day at
30°C
and up to two days at 25°C.  Following centrifugation, the plasma may be
stored for an additional five days at 2°
to 8°C before testing. Plasma separated from the cells
may be stored for longer periods of time at £ -20°C before testing.  D.No
adverse effect on assay performance was observed when plasma was subjected to
three freeze-thaw cycles.  E.Mix
thawed plasma thoroughly and centrifuge for 10 minutes at 1000 to 3000 X g
before testing.  Centrifugation times
and speeds for thawed PPT tubes must be validated by the user.  F.Other
collection and storage conditions should be validated by the user.  If specimens are to be shipped, they should
be packaged and labeled in compliance with applicable federal and international
regulations covering the transport of clinical specimens and etiologic
agents.(14)  G.False
positive results may occur if cross contamination of specimens is not
adequately controlled during specimen handling and processing.  H.Specimen
Pooling  The Chiron CPT Pooling
Software, used in combination with the TECAN GENESIS RSP, performs sample
scanning and pooling operations that combine aliquots from individual samples
into a single Master Pool Tube, which may be used for further testing.  PROCEDURAL
NOTES  A.RUN
SIZE  When the average run size
is 55 tests or more, P/N 301135 should yield 5000 tests per kit.  Smaller run sizes will result in a lower
yield.  Each run of up to 100 tests must
contain 3 replicates each of the Negative Calibrator, the Positive Calibrator
and the Blank.  B.EQUIPMENT
PREPARATION  1.Three
dedicated circulating water baths must be used: one for target capture and
pre-amplification (60° ± 1°C),
one for amplification (41.5° ± 1°C)
and one for hybridization and selection (60°
± 1°C).  An
additional water bath is required to be maintained at 23°
± 4°C for the step preceding detection.  2.Equilibrate
circulating water baths to 60° ± 1°C
for target capture and 41.5° ± 1°C
for amplification incubations.  3.Prepare
the TECAN GENESIS RSP for use according to instructions in the Operators
Manual.  4.Prepare
the Chiron® Procleix® TCS for use according to
instructions in the Operators Manual.  5.Wipe
work surfaces and pipettors daily with diluted bleach (0.5% sodium hypochlorite
in water).  Allow bleach to contact
surfaces and pipettors for at least 15 minutes and then follow with a water
rinse.  A BLEACH ALTERNATIVE MAY BE
USED IN PRE-AMPLIFICATION AREAS ONLY. 
DO NOT USE BLEACH ALTERNATIVES IN AMPLIFICATION AREAS OR IN AREAS
SUSPECTED TO BE CONTAMINATED WITH AMPLIFICATION PRODUCTS.  DO NOT USE DEACTIVATION FLUID ON SURFACES.  6.Equilibrate
a circulating water bath to 60° ± 1°C
for hybridization and selection incubations. 
Prepare an additional container of water at 23°
± 4°C for cool down prior to detection.  INO135 Rev. 1  5 
   7.Setup
procedures for the Chiron Procleix HC+ Luminometer are given in the Operators
Manual.  C.REAGENTS  1.Add
all reagents using an Eppendorf repeat pipettor (or equivalent) capable of
delivering specified volume with ± 5% accuracy and a precision of <
5% CV.  Check pipettor functionality
monthly and calibrate regularly.  2.To
minimize waste of Amplification, Oil, Enzyme, Probe, and Selection Reagents,
aliquot each reagent for a given run size. 
Aliquoting must be performed after reagent preparation using sterile,
polypropylene conical tubes with sealing caps in an area that is template and
amplicon free.  The aliquoting area must
be wiped down with diluted bleach (0.5% sodium hypochlorite in water) before
and after the aliquoting process.  A
BLEACH ALTERNATIVE MAY BE USED IN PRE-AMPLIFICATION AREAS ONLY.  DO NOT USE BLEACH ALTERNATIVES IN
AMPLIFICATION AREAS OR IN AREAS SUSPECTED TO BE CONTAMINATED WITH AMPLIFICATION
PRODUCTS.  The aliquoted reagents must
be used the same day the aliquoting was performed.  DO NOT store reagents in the aliquot conical tubes.  3.A
color change will occur in the reaction tube after the addition of Amplification
Reagent, Enzyme Reagent, Probe Reagent, and Selection Reagent.  D.WORK
FLOW  1.To
minimize the possibility of laboratory areas from becoming contaminated with
amplicon, the laboratory area should be arranged with a uni-directional
workflow.  Proceed from reagent
preparation to sample preparation to amplification and then to detection
areas.  Samples, equipment and reagents
should not be returned to the area where a previous step was performed.  Also, personnel may not move from the
dedicated HPA area back into previous work areas without proper
anti-contamination safeguards.  2.Perform
reagent preparation in a template free area.  3.Perform
Target Capture and Pre-Amplification steps in an amplicon-free area.  4.Perform
Hybridization Protection Assay in an area separate from the reagent preparation
and amplification areas.  Note:      Upon
completion of pipetting specimens (individual samples or pools) into TTUs, the
TTUs are removed from the deck and loaded into a TTU rack.  If the operator needs to pipette the same
specimens (individual samples or pools) for a different Procleix assay, the
empty calibrator tubes and TCR trough must be discarded but the specimens may
be left on the deck.  The operator
should then change gloves after emptying the used empty calibrator tubes and
TCR trough.  Clean TTUs should then be
loaded into the TTU carriers on the deck. 
Proceed with step A.3, under INSTRUCTIONS FOR USE.  E.TEMPERATURE  1.The
Target Capture, Amplification, Hybridization and Selection reactions are
temperature dependent.  Therefore, it is
imperative that the water baths are maintained within the specified temperature
range.  Use a calibrated thermometer.  2.Room
temperature is defined as 15° to 30°C.  3.Detection
is sensitive to temperature.  The
laboratory temperature in the detection area must be 21°
to 27°C.  F.TIME  1.The
Target Capture, Amplification, and Hybridization Protection Assay steps are all
time dependent.  Adhere to specific
times outlined in INSTRUCTIONS FOR USE. Use a calibrated timer.  G.VORTEXING  1.Proper
vortexing is important to the successful performance of the Procleixâ
WNV Assay.  Vortex equipment speed
settings may vary.  Start the vortexor
at low speed and then adjust upward to allow reaction mixture to reach and
maintain a height within the upper half of all tubes.  The reaction mixture should never touch the sealing cards.  It is
critical to have a homogeneous mixture after the additions of the Probe Reagent
and Selection Reagent.  H.PIPETTING  1.All
the pipettes used in the Target Capture, Amplification and HPA steps must be
dedicated for these purposes only to avoid cross contamination.  2.Take
care to deliver reagents, excluding working TCR, to each tube without inserting
pipette tip into the tube or touching the rim of the tube to minimize the
chance of carryover from one tube to another.  I.MANUAL
SPECIMEN PIPETTING  1.When
using the manual sample/TCR pipetting method, improper pipetting technique will
affect the results of the assay.  See PROCEDURAL
NOTES, Section H. In order to avoid the loss of Positive ID Tracking,
verification of correct sample ID by a second individual is recommended.  2.Ensure
that the TTU is oriented in the rack with the pointed end on the left side and
the rounded end on the right side of the rack. 
Pipette the first calibrator into the first tube next to the pointed end
of the TTU.  Samples are pipetted from
left to right.  3.Use
a new pipette tip for each sample and dispose of the tip in a biological waste
container after use.  Take care to avoid
cross-contamination by pipetting the specimens and discarding the used pipette
tips without passing over open tubes or touching laboratory surfaces or other
pieces of equipment.  4.To
avoid the risk of contamination, clean and decontaminate manual sample
pipettors between assay runs.  5.Ensure
proper sample placement into the correct TTU position as indicated on the
manual work list record.  J.DECONTAMINATION  1.The
extremely sensitive nature of the test makes it imperative to take all possible
precautions to avoid contamination. 
Laboratory bench surfaces, and pipettes must be decontaminated daily
with diluted bleach (0.5% sodium hypochlorite in water).  Allow bleach to contact surfaces for at
least 15 minutes and then follow with a water rinse.  Chlorine solutions may pit equipment and metal.  Thoroughly rinse bleached equipment to avoid
pitting.  2.A
BLEACH ALTERNATIVE MAY BE USED IN PRE-AMPLIFICATION AREAS ONLY.  DO NOT USE BLEACH ALTERNATIVES IN
AMPLIFICATION AREAS OR IN AREAS SUSPECTED TO BE  INO135 Rev. 1  6 
   CONTAMINATED
WITH AMPLIFICATION PRODUCTS.  3.Reactions
must be decontaminated with Deactivation Fluid as described in the detection
procedure.  K.SEALING
CARDS  1.When
applying sealing cards, cover the TTUs with the sealing card and press gently
to ensure complete contact with all of the tubes.  Always use a new sealing card. 
DO NOT re-use sealing cards.  2.When
removing sealing cards, carefully lift and peel in one continuous motion to
avoid aerosols and cross contamination. 
Immediately dispose of card in appropriate waste container.  INSTRUCTIONS FOR USE:  PROCLEIXâ WNV ASSAY ON INDIVIDUAL DONOR PLASMA
SAMPLES OR ON POOLED PLASMA SAMPLES  All
specimens (individual donations or pooled samples) should be run in singlet in
the initial Procleixâ WNV Assay.  Procleixâ WNV Assay Calibrators are to be used with
the corresponding master lot of the Procleix WNV Assays.  The operator must check to ensure that the
Procleix WNV Assay Calibrators are used with the corresponding master lot of
kit reagents as indicated on the master lot sheet enclosed with each shipment
of Procleix WNV Assay Calibrators.  To run the Procleix WNV
Assay for the detection of WNV RNA, follow the steps below for Target Capture,
Amplification and Hybridization Protection Assay.  Note: Continuous Process
Flow:  All process steps
described below are intended to be completed in a continuous flow with a
minimal, if any, delay between steps.  A.TARGET CAPTURE  The
Procleix WNV Assay has been verified using the TECAN GENESIS RSP.  The use of manual pipetting requires
additional operator training and demonstration of proficiency.  Repeat pipettors used in this step must be
dedicated for use only in the TARGET CAPTURE steps.  IF USING THE TECAN
GENESIS RSP PIPETTOR:  1.Start
the Chironâ Procleixâ
Assay Software.  Refer to the Procleix
Assay Software Operators Manual for software operating instructions.  2.Place
TTU Carriers on the TECAN GENESIS RSP deck according to the deck layout
indicated on the screen.  Load
sufficient Ten Tube Units (TTUs) for the run into TTU Carriers.  3.Mix
working Target Capture Reagent thoroughly to resuspend microparticles.  This is important before putting into the
TECAN GENESIS RSP reagent trough.  Put
sufficient working Target Capture Reagent into the reagent trough and place on
the TECAN GENESIS RSP deck as indicated on the deck layout screen.  If pipetting can not be completed within 2
hours, remix prior to use.  4.Place
calibrators, blank, and samples into TECAN 16-Tube Strip Racks.  Place TECAN 16-Tube Strip Racks on the TECAN
GENESIS RSP deck according to the deck layout indicated on the screen.  Note: Samples may already
be in strip racks, on the Tecan deck, from pipetting a prior Procleix assay.  5.Reference
the Procleixâ Assay Software Operators Manual for
instructions on pipetting.  The TECAN
GENESIS RSP will read bar codes of all carriers, TTUs, calibrators, blanks, and
samples.  The TECAN GENESIS RSP will
pipette 400 mL of working TCR into each reaction tube and then
pipette 500 mL each of calibrators, blank, and test samples
into assigned reaction tubes.  An
electronic work list will be created.  6.When
all samples have been pipetted, transfer the TTUs to a TTU rack.  Cover the TTUs with sealing cards.  See PROCEDURAL NOTES.  7.Vortex
the rack of TTUs a minimum of 20 seconds and until magnetic microparticles are
resuspended.  See PROCEDURAL NOTES.  8.Rack
may remain at room temperature up to 75 minutes prior to proceeding to the 60°C
± 1°C incubation.  9.Incubate
the tubes in a water bath at 60° ± 1°C
for 20 minutes ± 1 minute.  10.Remove
the rack of TTUs and transfer to target capture area.  11.Incubate
the rack of TTUs on the lab bench at room temperature for 14 minutes to 20
minutes.  12.Transfer
the rack of TTUs to the Chironâ Procleixâ
TCS separation bay for 9 to 20 minutes.  13.Carefully
remove and dispose of the sealing cards. 
See PROCEDURAL NOTES.  14.Aspirate
the solution from each tube according to the Procleixâ
TCS Operators Manual.  15.Add
1 mL of Wash Solution to each tube. 
Cover the TTUs with sealing cards. 
See PROCEDURAL NOTES.Remove
the rack of TTUs from the Chiron Procleix TCS separation bay and vortex to
resuspend the microparticle pellets. 
See PROCEDURAL NOTES.  16.Place
the rack of TTUs on the Chiron Procleix TCS separation bay for  4 to 10 minutes.  17.Carefully
remove and dispose of the sealing cards. 
See PROCEDURAL NOTES.  18.Aspirate
the solution from each tube according to the Procleix TCS Operators Manual.  19.Add
1 mL of Wash Solution to each tube. 
Cover the TTUs with sealing cards. 
Remove the rack of TTUs from the Target Capture System separation bay
and vortex to resuspend the microparticle pellets.  See PROCEDURAL NOTES.  20.Place
the rack of TTUs on the Chiron Procleix TCS separation bay for 4 to 10 minutes.  21.Carefully
remove and dispose of the sealing cards. 
See PROCEDURAL NOTES.  22.Completely
aspirate the solution from each tube according to the Procleix TCS Operators
Manual.  Cover the TTUs with a sealing
card.  23.Remove
the rack of TTUs from the Chiron Procleix TCS separation bay and proceed
directly to Amplification.  IF
USING THE MANUAL SAMPLE PIPETTING METHOD:  The
assay results within the run report will be marked M indicating that the
specimens were manually pipetted.  1.For
sample tracking, an electronic worklist must be created using the Procleix
Worklist Editor software.  Refer to the
Worklist Editor Operators Manual for instructions.  Verification of correct sample ID on the  INO135 Rev. 1  7 
    worklist with the
specimen tubes and with the detailed assay run report by a second individual is
recommended.  2.Load
sufficient Ten Tube Units (TTUs) for the run into a TTU rack.  3.Thoroughly
mix working TCR immediately before use to resuspend microparticles.  4.Refer
to the worklist and carefully pipette 400 mL
of working TCR to each reaction tube that will contain a specimen.  To dispense, insert the tip approximately
one quarter of the way into the tube at an angle and pipette working TCR down
the side of the tube.  Always pipette
the working TCR first, followed by the specimen.  5.Pipette
specimens. a.Refer
to the worklist to identify the TTU number with the corresponding calibrator
and test specimen identification numbers. b.Aspirate
500 mL of each calibrator, external quality control
(if used), blank, or test sample from its collection tube using a single
channel pipettor with corresponding filtered disposable tip.  Insert only the end of the pipette tip into
the specimen.  Do not disturb the
sediment, if any. c.To
dispense, insert the pipette tip halfway into the tube taking care not to touch
the sides of the upper half of the tube with the pipette tip.  At an angle, pipette the specimen down the
side of the bottom half of the tube. 
Hold down the plunger of the pipettor while removing it from the tube.  Take care to avoid touching the rim or the
side of the tube with the pipette tip when removing it from the tube.  6.Replace
pipette tip with a new tip and repeat Step 5 until all specimens have been
pipetted.  7.Visually
inspect tubes to ensure proper specimen volume and working TCR volume have been
dispensed.  8.Cover
the TTUs with sealing cards.  See PROCEDURAL
NOTES. Proceed to Step 7 of section titled If Using the TECAN GENESIS
RSP 150/8 Pipettor, above.  B.AMPLIFICATION  The
repeat pipettors used in this step must be dedicated for use only in
AMPLIFICATION steps.  DO NOT USE BLEACH ALTERNATIVES IN THIS AREA.  1.Carefully
remove and dispose of the sealing cards. 
See PROCEDURAL NOTES.  2.Deliver
75 mL of Amplification Reagent to the bottom of each
tube using the dedicated repeat pipettor. 
Take care to deliver the reagent to the bottom of each tube without
inserting the pipette tip into the tube or touching the rim of the tube.  3.Add
200 mL of Oil to each reaction tube using the
dedicated repeat pipettor.  Angle the
pipette tip toward the sides of the tubes, not straight to the bottom, to avoid
splashback.  4.Cover
the TTUs with sealing cards.  See PROCEDURAL
NOTES.  5.Vortex
the rack of TTUs a minimum of 20 seconds and until all microparticles are
resuspended.  Ensure that magnetic
particles are no longer adhering to the walls of the tube, and are evenly
dispersed in the aqueous phase.  6.Incubate
the TTUs in a water bath at 60° ± 1°C
for 10 minutes ± 1 minute, then at 41.5°
± 1°C for 9 to 20 minutes.  7.Leaving
the rack of TTUs at 41.5° ± 1°C,
carefully remove and dispose of the sealing cards.  See PROCEDURAL NOTES.  
Proceed immediately to enzyme addition. 
Add 25 mL of the Enzyme Reagent into each tube using the
dedicated repeat pipettor.  Take care to
deliver the reagent to the bottom of each tube without inserting the pipette
tip into the tube or touching the rim of the tube.  Place new sealing cards over the TTUs.  See PROCEDURAL NOTES. Remove the rack of TTUs from the water bath and shake to mix.  DO NOT VORTEX.  Minimize the time the tubes are out of the water bath.  8.Incubate
the rack of TTUs in the water bath at 41.5°
± 1°C for 60 minutes ± 5 minutes.  9.Remove
the rack of TTUs from the water bath and transfer it to the Hybridization
Protection Assay area.  Rack may remain
at room temperature for up to 30 minutes prior to the addition of Probe
Reagent.  C.HYBRIDIZATIONPROTECTION ASSAY (HPA)  The
repeat pipettor used in this step must be dedicated for use only in
HYBRIDIZATION PROTECTION ASSAY.  A separate, dedicated
location for the Hybridization Protection Assay (HPA) step is recommended to
minimize amplicon contamination in the assay. 
This dedicated area should be on a separate bench in a separate area
from the reagent and sample preparation and amplification areas.  DO NOT USE
BLEACH ALTERNATIVES IN THIS AREA.  1.Hybridization a.Carefully
remove and dispose of the sealing cards. 
See PROCEDURAL NOTES. b.Add
100 mL of Probe Reagent into each tube using the
dedicated repeat pipettor.  Take care to deliver the reagent to the bottom of each
tube without inserting the pipette tip into the tube or touching the rim of the
tube.  Angle the pipette tip toward the
sides of the tubes, not straight to the bottom, to avoid splashback. c.Cover
the TTUs with sealing cards.  See PROCEDURAL
NOTES. d.Vortex
the rack of TTUs a minimum of 20 seconds and until a homogeneous solution is
achieved.  To avoid possible
contamination, do not allow reaction mixture to come in contact with the
sealing card.  See PROCEDURAL NOTES. e.Incubate
the rack of TTUs in a dedicated water bath at 60°
± 1°C for 15 minutes ± 1 minute.  2.Selection a.Remove
the rack of TTUs from the 60° ± 1°C
water bath.  Carefully remove and
dispose of the sealing cards.  See PROCEDURAL
NOTES. b.Add
250 mL of Selection Reagent to each tube using a
repeat pipettor.  Take care to deliver
the reagent to the bottom of each tube without inserting the pipette tip into
the tube or touching the rim of the tube. 
Angle the pipette tip toward the sides of the tubes, not straight to the
bottom, to avoid splashback. c.Cover
the TTUs with sealing cards.  See PROCEDURAL
NOTES.  Vortex the rack of TTUs a
minimum of 20 seconds and until a homogeneous solution is achieved.  To avoid possible contamination, do not
allow reaction mixture to come in contact with the sealing card.  See PROCEDURAL NOTES.  INO135 Rev. 1  8 
   d.Return
the rack of TTUs to the 60° ± 1°C
water bath for 10 minutes ± 1 minute. e.Remove
the rack of TTUs from the 60° ± 1°C
water bath. f.Cool
the rack of TTUs in a 23° + 4°C
container of water for a minimum of 10 minutes while preparing for Detection
(step 3a). g.Remove
the rack of TTUs from the 23° ± 4°C
container of water onto absorbent material.  3.Detection a.Prepare
the Chiron Procleix HC+ Luminometer for operation as indicated in the
Operators Manual.  Ensure that there
are sufficient volumes of Auto Detect 1 and Auto Detect 2 to complete the
tests. b.Select
the WNV assay protocol from the Chiron Procleix WNV System Software menu. c.Carefully
remove and dispose of the sealing cards. 
See PROCEDURAL NOTES. d.Before
transferring TTUs to the luminometer, wipe the outside of the tubes using an
absorbent tissue dampened with deionized water.  This will ensure that no residue is present on the outside of the
tubes and will help reduce static electricity that may affect luminometer
readings. e.Transfer
TTUs to the luminometer according to the software instructions.  Note: Tube reading should be completed
within 75 minutes after completing the selection reaction (step 2e in Selection
procedure). f.When
the analysis is complete, remove the TTUs from the luminometer. g.After
removing the TTUs from the luminometer, add at least 1mL Deactivation Fluid to
each tube.  Allow to sit at room
temperature for at least 30 minutes before disposing the contents of the
tubes.  This will help to prevent
contamination of the laboratory environment with amplicon. h.TTU
racks should be decontaminated by complete immersion in diluted bleach (0.5%
sodium hypochlorite in water) for a minimum of 15 minutes.  The bleach should then be rinsed off with
water and the rack may be allowed to air dry or may be wiped dry.  QUALITY CONTROL PROCEDURES:  PROCLEIXâ WNV ASSAY ON INDIVIDUAL DONOR PLASMA
SAMPLES OR ON POOLED PLASMA SAMPLES  I.ACCEPTANCE CRITERIA FOR THE PROCLEIXâ WNV ASSAY  Run
Validity Criteria  A.A
run is valid if the minimum number of calibrators is valid and calibrators meet
acceptance criteria (see II below).  1.In
a Procleixâ WNV Assay run, at least 4 of the 6
calibrator replicates must be valid.  At
least 2 of the 3 negative calibrator replicates and 2 of the 3 positive
calibrator replicates must be valid.  2.The
Procleix System Software will automatically invalidate a run if less than the
minimum number of calibrators is valid. All specimens in an invalid run due to
calibrators must to be retested.  3.Cutoff
values will be automatically calculated for Internal Control (flasher) and
Analyte (glower) in a valid run (see II.A. below).  4.For
Positive Calibrators or samples which are Reactive for Analyte (glower signal),
an Internal Control signal below the cutoff is not used to invalidate the
result.  5.The
Blank is not used to determine run validity. 
No results are reported for the Blank.  B.Procleixâ 
WNV Assay. The Procleix WNV System Software will print an alert on
the run report when more than 10% of the calibrators and specimens in a run are
invalid (see the Procleix HC+ Luminometer Operators Manual for details).  Specimens that are invalid due to
insufficient sample or TCR are not included in the calculation of the 10%
invalid criterion.  C.For
runs that exceed the 10% invalid rate, review of package insert procedures
should be performed to monitor for operator errors.  In addition, the run report should be reviewed using the criteria
described below.  1.If
the invalid specimens are all from the same TTU, those specimens contributing
to the 10% invalid rate may have been inadequately washed, or erroneous reagent
addition may have occurred.  All
nonreactive and invalid specimens in the affected TTU should be repeated.  2.If
the invalid specimens are randomly located throughout the run, there were
calibrator failures, and no specific procedural error can be identified, the
nonreactive and invalid specimens must be repeated.  Note: Reactive specimens
in a manually invalidated run due to the 10% invalid alert criteria, must
become the test of record.  The
specimens should be resolved according to the resolution algorithm for reactive
specimens, as explained in the INTERPRETATION OF RESULTS section, step
4.  D.An
assay run or an individual sample may also be invalidated by an operator if
specific technical/operator/instrument difficulties were observed and
documented.  If individual samples are
invalidated by an operator, then the percent invalid rate must be manually
recalculated.  The individual invalid
specimens must be repeated.  II.ACCEPTANCE CRITERIA FOR THE CALIBRATION AND
CALCULATION OF CUTOFF  Procleixâ WNV Assay Negative
Calibrator Acceptance Criteria  Each individual Negative
Calibrator (NC) must have an Internal Control (IC) value greater than or equal
to 75,000 RLU and less than or equal to 400,000 RLU.  Each individual Negative Calibrator must also have an Analyte
value less than or equal to 40,000 RLU and greater than or equal to 0 RLU.  If one of the Negative Calibrator values is
invalid due to an IC value or an Analyte value outside of these limits, the
Negative Calibrator mean (NCx) will be recalculated based upon the
two acceptable values.  The run is
invalid and must be repeated if two or more of the three Negative Calibrator
values have IC values or Analyte values that are outside of these limits.  INO135 Rev. 1  9 
   Determination of the mean
of the Negative Calibrator values (NCx) for Internal Control [NCx (Internal
Control)].  Example: Negative Calibrator
  
  Internal Control
  Relative Light Units1
  
  235,0002
  
  200,0003
  
  210,000Total Internal
  Control RLU =
  
  645,000  NCx(Internal
  Control) =
  Total Internal
  Control RLU
  = 215,0003  Determination of the mean
of the Negative Calibrator values (NCx)for Analyte [NCx(Analyte)].  Example: Negative Calibrator
  
  Analyte
  Relative Light Units1
  
  14,0002
  
  16,0003
  
  15,000Total Analyte
  RLU =
  
  45,000  NCx(Analyte) =
  Total Analyte
  RLU
  = 15,0003  Positive
Calibrator Acceptance Criteria  Individual Positive
Calibrator (PC) Analyte values must be less than or equal to 2,700,000 RLU and
greater than or equal to 400,000 RLU. 
If one of the Positive Calibrator values is outside these limits, the
Positive Calibrator mean (PCx) will be recalculated based upon the
two acceptable Positive Calibrator values. 
The run is invalid and must be repeated if two or more of the three
Positive Calibrator Analyte values are outside of these limits.  IC values may not exceed 500,000 RLU.  Determination of the mean
of the Positive Calibrator (PCx) values for Analyte [PCx(Analyte)].  Example: Positive Calibrator
  
  Analyte
  Relative Light Units1
  
  1,250,0002
  
  1,500,0003
  
  1,150,000Total Analyte
  RLU =
  
  3,900,000  PCx(Analyte)
  =
  Total Analyte
  RLU
  = 1,300,0003  Calculation
of the Internal Control Cutoff Value  Internal Control Cutoff
Value = 0.5 X [NCx(Internal Control)]  Using values given in the
Negative Calibrator example above:  Internal Control Cutoff
Value = 0.5 X (215,000)  Internal Control Cutoff
Value = 107,500 RLU  Calculation
of the WNV Analyte Cutoff Value  Analyte Cutoff Value = NCx(Analyte) + [0.03 X WNV PCx (Analyte)]  Using values given in the
Negative Calibrator and Positive Calibrator examples above:  Analyte Cutoff Value =
15,000 + (0.03 X 1,300,000)  Analyte Cutoff Value =
54,000 RLU  Summary of Acceptance Criteria for
Procleixâ
WNV Assay  Acceptance Criteria:  Negative CalibratorAnalyte
  
  >
  0 and < 40,000 RLUInternal Control
  
  >
  75,000 and < 400,000 RLUPositive CalibratorAnalyte
  
  >
  400,000 and < 2,700,000 RLUInternal Control
  
  <
  500,000 RLU  Summary of Cutoff Calculations for
Procleixâ
WNV Assay  Analyte Cutoff =
  
  NC Analyte Mean
  RLU+ 0.03 X (PC
  Analyte Mean RLU)Internal Control Cutoff =
  
  0.5 X (Negative
  Calibrator IC Mean RLU)  INTERPRETATION OF RESULTS  All
calculations described above are performed by the Chironâ Procleixâ WNV System Software.  Two cutoffs are determined for the WNV
assay:  one for the Analyte signal
(glower signal) termed the Analyte Cutoff and one for the Internal Control
signal (flasher signal) termed the Internal Control Cutoff.  The calculation of these cutoffs is shown
above.  For each sample, an Analyte signal
RLU value and Internal Control signal RLU value is determined.  Analyte signal RLU divided by the Analyte
Cutoff is abbreviated as the Analyte Signal/Cutoff (S/CO) on the report.  For a sample with Analyte
signal less than the Analyte Cutoff (i.e., Analyte S/CO < 1), the Internal
Control (IC) signal must be greater than or equal to the Internal Control
Cutoff (IC Cutoff) for the result to be valid. 
In this case the Internal Control result will be reported as Valid and the sample is reported as Nonreactive.  For a sample with the Analyte signal less than the Analyte Cutoff
(i.e., Analyte S/CO < 1) and the Internal Control signal less than the
Internal Control Cutoff, the Internal Control Result will be reported as Invalid and the sample result is reported
as Invalid.  For all samples, the Internal Control signal
may not exceed 500,000 RLU.  The sample
will automatically be reported as Invalid
with the Chironâ Procleixâ
WNV System Software.  Summary
of Sample Validity:  Sample
  Interpretation
  
  Internal Control
  ResultNonreactive
  
  Valid
  
  Analyte S/CO
  < 1 andIC >
  IC Cutoff andIC <
  500,000 RLUReactive
  
  (Not used)
  
  Analyte S/CO >
  1andIC <
  500,000 RLU  INO135 Rev. 1  10 
   1.Any
specimen with an invalid Procleixâ WNV Assay
result, must be retested in the same assay in singlet.  2.If
at any point in the testing algorithm there is insufficient volume to complete
the testing then an alternate specimen from the index donation may be used as
long as the storage criteria in the package insert are met.  3.Specimens
with a valid internal control and with an S/CO less than 1.00 in the Procleix
WNV Assay are considered Nonreactive for WNV RNA. a.IF
THE NONREACTIVE SPECIMEN IS A POOL, then each of the individual specimens
comprising the pool is considered Nonreactive and no further testing is
required. b.IF
THE NONREACTIVE SPECIMEN IS FROM AN INDIVIDUAL DONATION, then the individual
specimen is considered Nonreactive for WNV and no further testing is required.  4.Specimens
with S/CO greater than or equal to 1.00 are considered Reactive. a.IF
THE REACTIVE SPECIMEN IS A POOL, then each of the individual specimens
comprising the pool is tested with the Procleix WNV Assay. (1)If
an individual specimen tests Nonreactive with the Procleix WNV Assay, then the
specimen is considered Nonreactive for WNV and no further testing is required.  (2)If
an individual specimen tests Reactive with the Procleix WNV Assay, then the
individual specimen is considered Reactive for WNV.  Further clarification of the Reactive specimens may be obtained
by testing another sample from the index donation with the Procleix WNV Assay,
in an Alternate NAT and/or by follow-up testing. b.IF
THE REACTIVE SPECIMEN IS FROM AN INDIVIDUAL DONATION, then the individual
specimen is considered Reactive for WNV. 
Further clarification of the Reactive specimens may be obtained by
testing another sample from the index donation with the Procleix WNV Assay, an
Alternate NAT and/or by follow-up testing.  5.Reactive
specimens in a manually invalidated run due to the 10% invalid alert criteria,
as explained in the ACCEPTANCE CRITERIA FOR THE PROCLEIX WNV ASSAY,
section C, must become the test of record.  Any reactive result (analyte signal/cutoff > 1) should
be resolved according to the resolution algorithm for reactive specimens, as
explained in the INTERPRETATION OF RESULTS section, step 4.  LIMITATIONS OF THE PROCEDURE  Assays must be performed,
and results interpreted according to the procedures provided.  Deviations from these
procedures may produce unreliable results. Adverse shipping, storage conditions
of outdated calibrators and/or reagents may produce erroneous results.  BIBLIOGRAPHY  1.Campbell G. L., A. A. Marfin, R. S. Lanciotti, and D.
J. Gubler. 2002.  West Nile
virus.  Lancet infect Dis. 2:519-529. 2.Petersen L. R., and A. A. Marfin. 2002.
West Nile Virus: A primer for the clinician. 
Ann Intern Med. 137:173-179. 3.Centers for Disease Control.  January 24, 2002.  West Nile virus (WNV) infection: information
for clinicians.  Clinical features.  Website posting. 4.Centers for Disease Control.  January 8, 2003.  West Nile virus: virus history and
distribution. Website posting. 5.Centers for Disease Control.  December 23, 2002.  West Nile virus: questions and answers.  Website posting. 6.Centers for Disease Control.  September 13, 2002.  Public health dispatch:  investigation of blood transfusion
recipients with West Nile virus infections. 
MMWR.  51:823. 7.Centers for Disease Control.  2002. 
CDC Public health dispatch; possible West Nile virus transmission to an
infant through breast-feeding.  MMWR. 51: 877-878. 8.Giachetti,  C., J. M. Linnen, D. P. Kolk, J. Dockter, et al.  2002. 
Highly sensitive multiplex assay for detection of human immunodeficiency
virus type 1 and hepatitis C virus RNA. J Clin Microbiol. 40:2408-2419. 9.Kacian, D. L. and T. J. Fultz. 1995.  Nucleic acid sequence amplification
methods.  U.S.  Patent 5,399,491. 10.Arnold, L. J., P. W. Hammond, W. A. Wiese, and N. C.
Nelson.  1989.  Assay formats involving
acridinium-ester-labeled DNA probes. 
Clin Chem 35:1588-1594. 11.Nelson, N. C., A. Cheikh, E. Matsuda and M. Becker.  1996. 
Simultaneous detection of multiple nucleic acid targets in a homogeneous
format.  Biochem. 35:8429-8438. 12.National Committee for Clinical Laboratory Standards.  1986. 
Clinical laboratory hazardous waste: 
proposed guidelines.  NCCLS
Document GP5-P.  Villanova, PA. 13.U. S. Environmental Protection Agency.  EPA guide for infectious waste
management.  Washington,  DC; 
U.S. Environmental Protection Agency, Publication No. EPA/530-SW-86-014.
1986. 14.Title 42, Code of Federal Regulations, Part
72. 1992. 15.29 CFR Part 1910.1030.  Occupational exposure to bloodborne
pathogens; Final Rule,  Federal
Register/Vol. 56, No. 235/
December 6, 1991.  IN0135 Rev. 1 2003-02  Developed
and manufactured by: Gen-Probe Incorporated 10210 Genetic Center
Drive San Diego, CA 92121 (858) 410-8000  Distributed
in U.S. by: Chiron Corporation 4560 Horton Street Emeryville, CA 94608-2916 Telephone (in U.S.):
(800) CHIRON-8 (510) 655-8730  Distributed
in rest of world by: Chiron Ireland, Limited United Drug House Belgard Road, Tallaght Dublin 24, Ireland 353 (0) 1 404 1599  INO135 Rev. 1  11 
   Chiron
Blood Testing Technical Support: (North America) Telephone: (800) 452-6877 FAX: (800) 462-3938  (Europe, Middle East,
Latin America, Africa) Hot Line: +800 CHIRON BT or + 33 1 55 49 00 36 Telephone: +33 (1) 55 49
01 65 FAX: +33 (1) 55 49 01 69  (Asia/Pacific) Telephone: +61 (0) 410 44
5810 FAX: +61 (0) 299 74 5411  Chiron, RIBA and Procleix
are trademarks of Chiron Corporation; TECAN, GENESIS (stylized), and RSP are
trademarks of Tecan AG: eppendorf (stylized) and COMBITIPS are trademarks of
Eppendorf-Netheler-Hinz GmbH; PROCLIN (stylized) is a trademark of Rohm and
Haas Company.  This product and its
intended use are covered by one or more of the following: U.S. patent no.
5,185,439; 5,283,174; 5,399,491; 5,437,990; 5,480,784; 5,585,481; 5,612,200;
5,639,604; 5,656,207; 5,656,744; 5,658,737; 5,696,251; 5,756,011; 5,756,709;
5,827,656; 5,840,873; 5,888,779; 5,948,899; 5,955,261; 6,004,745; 6,031,091;
6,090,591;6,110,678;
6,245,519; 6,280,952; 6,410,276; 6,414,152; RE37,891; and international
counterparts.  Ó
2003 Gen-Probe Incorporated  INO135 Rev. 1  12 
   Schedule 2.9  PERFORMANCE
OBJECTIVES  Performance Objectives
  
  Target[***]
  
  Assay shall detect the
  target virus in [***].[***]
  
  IUO -[***][***]
  
  [***]
  
  [***][***]
  
  [***][***]
  
  [***][***]
  
  [***]
  
  [***][***]
  
  [***][***]
  
  [***]  41 
   Schedule 4.0  SERVICES  1.Maintenance
& Troubleshooting.  1.1ARC
shall store, handle and utilized the Products in accordance with the
Documentation, which may be amended from time to time.  1.2In
the event that any NTL resolves a problem with a Product, such problem shall be
logged in writing, including a description of the problem and the steps taken
by ARC to resolve it.   ARC shall
maintain a log for the Products and make available all such logs to Chirons
respective employees, contractors, subcontractors, or agents whose
responsibilities are to provide Services to ARC (Chiron Technical  Support)
upon request.  1.3If
a NTL is unable to resolve a problem it shall refer the problem to a Chiron
Technical Support representative for resolution in accordance with Paragraph 2
of this Schedule 4.0.  1.4Except
for routine maintenance and troubleshooting activities of Technologists as
provided in this Schedule 4.0, or otherwise with the prior
permission of Chiron, during the Term of this Agreement only Chiron or Chirons
agents shall install, service, alter or replace the Products.  2.Technical
Support and Service.  2.1Installation.  Chiron Technical Support personnel will
provide installation and set up of all Software on the Blood Screening Systems,
including verification of the operation of the Software in conjunction with the
Blood Screening Systems.  At such time
as Chiron determines that such setup and installation has been completed, the
ARC shall acknowledge the completion of such setup and installation and its
acceptance of the Blood Screening Systems in writing.  2.2Training.  For purposes of this Agreement, no
additional Trainers will be separately trained for purposes of the Products
acquired under this Agreement and the parties hereby agree that the number of
Trainers set forth in Section 2.2 of Schedule 4.0 of the 2002
Agreement shall, in addition to the training set forth in the 2002 Agreement,
also be trained for purposes of the Products acquired under this Agreement;
provided, however, that each of ARC and Chiron acknowledge and agree that the
training as provided  42 
   hereunder will be subject
to each partys scrutiny, and to the extent it is determined that the training
provided under the 2002 Agreement is inadequate for purposes of the Products
acquired under this Agreement, then one additional Trainer will be trained by
Chiron, at no additional cost to ARC, for each NTL.  Consistent with Section 2.2 of Schedule 4.0 of the 2002
Agreement, the Parties agree to meet and confer to develop a Train the Trainer
program for implementation by ARC. 
Except as set forth above, ARC shall be responsible for training of all
Technologists.  Additional training may
be requested by ARC from Chiron for an additional charge.  2.3Data
& Materials.  ARC shall make
available to Chiron on a timely basis all data, information and other materials
which are reasonably necessary for Chiron to perform the Services.  Such data shall be treated as confidential
Data in accordance with Section 6.7 of the Agreement.  Chiron shall have no liability for any
failure to perform, or for the late performance, of any Services to the extent
such Services require data, information or materials possessed, prepared or
generated by the ARC, if the ARC fails to provide the same in accordance with
Chiron reasonable requests.  2.4Support
and Service.  (a)Chiron
Technical Support to ARC shall be available 24 hours a day, 7 days a week
including weekends and holidays via telephone. 
The ARC will refer problems to Chiron Technical Support through a central
toll-free telephone number ([***]). 
A Chiron Technical Support representative will be available at this
number to receive problem referrals and provide troubleshooting assistance from
7:30 a.m. to 5 p.m. PST, Monday through Friday, holidays excepted (Normal
Support Hours).  If a Chiron
Technical Support representative is not reached by the initial ARC call, a
Chiron Technical Support representative will return the call to acknowledge
receipt of the problem referral and engage in a determination of the Priority
Status within one (1) hour.  Messages
left outside Normal Support Hours (including weekends and holidays) will
automatically page the on-call Technical Support personnel.  A Chiron Technical Support representative
will return all calls to acknowledge receipt of problem referral and engage in
a determination of the Priority Status within one (1) hour.  Required message information left outside
Normal Support Hours should include a contact name, phone number and brief
description of the problem.  Telephone
support will be initiated within the Priority/Response timeframes set forth
below.  If a problem  43 
   cannot be resolved
through telephone support within a reasonable amount of time, taking into
account its Priority status, the problem will be escalated to Chirons Product
Support Center, for analysis by Blood Screening System specialists and if
necessary, OEM support personnel.  If a
problem cannot be resolved following such escalation, Chiron Technical Support
will be dispatched to the NTL to provide service in accordance with the
Priority/Response Time Schedule set forth below.  Priority
  
  Response*Priority
  1:Products
  not operating and alternate or back-up equipment not available; screening
  cannot be performed
  
  Immediate telephone support
  Decision to dispatch Support
  Technician within 4 hours
  Support Technician on site ASAP but
  no later than 10 hours from initial problem referral
  Resolution ASAP, but no later than
  24 hours (may be temporary workaround)Priority
  2:Products
  operational but screening process (processing time) is affected
  
  Telephone support within 2 hours
  Support Technician on site within
  24 hours, if needed
  Resolution within 48 hoursPriority
  3: Products operational; no impact on screening process
  
  Telephone support next business
  day
  Work commenced within 24 hours
  Resolution within 1 week  
 *All timeframes are
approximate; actual response times may vary due to flight availability,
weather-related delays, nature of the problem, etc.  (b)Chiron
will maintain full records of all problem referrals and subsequent actions
pursuant to Regulations.  (c)Chiron
will provide a list of all field service technical personnel by name, including
contact information and a description of all certifications.  Such list shall be updated and confirmed
annually for all additions and deletions.  3.Warranty;
Limitation of Liability.  3.1Chiron
warrants that the Services provided by Chiron, its agents, employees or
contractors pursuant to this Agreement will be rendered in a competent
workmanlike manner and in accordance with industry standards.  3.2The
Services shall cover latent and hidden defects in design, material or
workmanship of the Products, and shall include  44 
   coverage of all Upgrades,
but shall exclude (i) replacement of operating supplies, necessaries,
consumables or expendable parts; (ii) repairs required due to improper storage,
accident, neglect, misuse, electrical stress, air conditioning, humidity
control, transportation, and force majeure events, use of non-approved
accessories, consumables or supplies, or causes other than intended normal use;
(iii) service for Products that have been tampered with, disassembled, altered,
changed or modified, maintained by anyone other than Trainers or Technologists
or repaired (or attempts have been so made) by anyone other than Chiron
Technical Support personnel or BMIT-certified Technologists under the direction
of Chiron Technical Support; (iv) and (v) service for any other equipment not
manufactured or supplied by Chiron.  3.3If
any applicable law implies a condition or warranty which cannot be excluded or
modified in this Agreement (a Requirement), then such Requirement is
deemed to be included in this Agreement.  45 
   Schedule 5.0  COMPENSATION  1.The
ARC agrees to pay to Chiron the agreed compensation in monthly increments, such
increments to be equal to the number of Reportable Results achieved by the ARC
each month, multiplied by the applicable Per Reportable Result amount from the
chart set forth below:  POOLED TESTING &
  OUTBREAK TESTING
  
  SINGLE UNIT TESTINGPer Reportable
  Result[***]
  
  [***]
  On or prior to the 5th business day
of each month during the Term, ARC shall provide Chiron with a report showing
the Reportable Results obtained through Pooled Testing, Single Unit Testing and
Outbreak Testing and Reagent Utilization Factor for the prior month for each
NTL.  On or prior to the 15th calendar
day of each month, Chiron shall prepare and deliver an invoice to ARC for each
NTL based on such report.  If ARCs
report is not timely received by Chiron, Chiron will prepare an invoice that
reflects the then current Standing Order for the applicable month multiplied by
the applicable Per Reportable Result amount. 
The Parties shall true-up payments made to the actual Reportable
Results achieved on a quarterly basis, rectifying any under- or over-payment on
the next subsequent invoice, without application of interest.  ARC shall make payment on invoices in
accordance with Section 5.2 of the Agreement.  Chiron and the ARC agree
to monitor the Reagent Utilization Factor at each NTL during the Term.  If the Reagent Utilization Factor for any
NTL exceeds the [***] (the Target RUF) [***], Chiron and the ARC shall use their
best endeavors to identify and correct the cause of the excess.  The Reagent Utilization
Factor shall be calculated for the ARC promptly following each successive ARC
Fiscal Year aggregating all NTLs.  If
the Reagent Utilization Factor for the ARC for any ARC Fiscal Year scores above
the applicable Target RUF (or such other factor as determined in accordance
with subparagraph (c)), Chiron shall invoice the ARC on the next subsequent
monthly invoice, and the ARC agrees to pay, the additional fee set forth below.  46 
   For each [***]
increment by which the actual Reagent Utilization Factor during each ARC Fiscal
Year exceeds the Target RUF, the [***]; provided that no additional fee
shall be payable hereunder to the extent that the cause of the Reagent
Utilization Factor exceeding the Target RUF is attributable to (A) a failure of
the Products to achieve the Performance Objectives set forth in
Section 2.9 of the Agreement, or (B) the implementation of an Upgrade or
Enhancement required by Chiron.  2.Termination
Reimbursement.  The Termination
Reimbursement shall be calculated as follows:  [***],  multiplied by  [***],  multiplied by  [***].  3.Additional
Supplies.  The following additional
supplies are available from Chiron at the prices set forth below.  The fees for such additional supplies may be
increased [***]
by Chiron in the event of, and in the amount of, any price increases by the
manufacturers of such additional supplies.  External Run Controls ([***])
  [***]Ten-Tube Units (TTUs) ([***])
  [***]Ten-Tube Cassettes
  (TTCs) ([***])
  [***]Proficiency Panels ([***])
  [***]  47